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F O R E W O R D
Evidence-Based Resource Guide 
Series Overview
The Substance Abuse and Mental Health Services 
Administration (SAMHSA), and specifically, the 
National Mental Health and Substance Use Policy 
Laboratory, is pleased to fulfill the charge of the 21st 
Century Cures Act and disseminate information on 
evidence-based practices and service delivery models 
to prevent substance misuse and help individuals 
with substance use disorders (SUD), serious mental 
illnesses (SMI), and serious emotional disturbances 
(SED) get the treatment and support that they need.
Treatment and recovery of individuals with opioid use 
disorder (OUD) can vary. These individuals may have 
co-occurring disorders, live in diverse parts of the 
country, and face a variety of socio-economic factors 
that help or hinder their treatment. All these factors 
bring complexities to evaluating the effectiveness of 
services, treatments, and supports.
Despite variations, substantial evidence is available 
to understand the types of services, treatments, and 
supports that reduce substance use, lessen mental 
health symptoms, and improve individuals’ quality of 
life. Communities are eager to take advantage of what 
has been learned to help individuals in need. 
The Evidence-Based Resource Guide Series is a 
comprehensive and modular set of resources intended 
to support health care providers, health care system 
administrators, and community members to meet the 
needs of individuals at risk for, experiencing, 
or recovering from substance use and mental 
health disorders. 
An important area of concern for SAMHSA is 
promoting policies and practices to lower the risk of 
overdose for persons with OUD who are or have been 
in contact with criminal justice systems. This guide 
will review literature and science, examine emerging 
and best practices, determine key components of peer-
reviewed models that affect policies and programs, and 
identify challenges and gaps in implementation.
Each guide in the series was developed through input 
from an expert panel made up of federal, state, and 
non-governmental participants. The expert panel 
for this Guide included accomplished scientists; 
practitioners and administrators from jails, prisons, and 
drug courts; law enforcement; community providers; 
and representatives from national corrections and 
OUD associations and organizations. They provided 
invaluable input based on their knowledge of criminal 
justice systems, evidence-based treatments and 
practices, and relevant experiences.
Identifying challenges and implementation strategies 
enhances organization and stakeholder readiness to 
change and encourages adoption of best practices, 
thus improving the care of individuals with OUD in 
criminal justice settings.
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Content of the Guide
Each guide contains a foreword and five chapters. The chapters are modular 
and do not need to be read in chronological order. The chapters are short and 
accessible to individuals such as health care providers, law enforcement, court 
personnel, jail and prison administrators, state and community corrections 
personnel, and community members who are working to meet the needs of 
individuals at risk for, experiencing, or recovering from substance use disorders.
FW Evidence-Based Resource Guide 
Series Overview
Introduction to the series. 
1 Issue Brief 
Overview of what is happening in the field. This chapter 
covers challenges to implementing MAT programs. It provides 
descriptions of approaches being used in the field.
2 What Research Tells Us
Current evidence on effectiveness of programs and practices to 
address use of MAT in criminal justice settings.
3 Examples of Medication-Assisted 
Treatment Programs in Criminal 
Justice Settings 
Descriptions of programs that use MAT in criminal justice settings.
4 Addressing Challenges to Implementing 
Evidence-Based Practices and Programs 
in Criminal Justice Settings
Practical information to consider when selecting and 
implementing programs and practices to address use of MAT 
in criminal justice settings.
5 Resources to Support Effective Use 
of Medication-Assisted Treatment in 
Criminal Justice Settings 
Guidance and resources for implementing evidence-based 
programs and practices, monitoring outcomes, and 
improving quality.  
Focus of the Guide
Following incarceration, 
individuals with OUD enter 
back into the environment 
where their substance use 
originated. Unfortunately, this 
puts the individual at high 
risk for relapse. Further, their 
tolerance for opioids is reduced 
while incarcerated. This puts 
the individual at high risk 
for overdose.   
This guide focuses on policies 
and practices that can be 
implemented to intervene 
during an individual’s time in 
the correctional system and 
upon release that moderate 
and mitigate the risk of 
overdose for persons with 
OUD after release.
One Piece of a 
Multipronged 
Approach
Research shows that 
implementing evidence-based 
practices requires 
a multipronged approach. 
This guide is one piece of an 
overall approach to implement 
and sustain change. Users 
are encouraged to review 
the SAMHSA website for 
additional tools and technical 
assistance opportunities.
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1
C H A P T E R
ISSUE BRIEF
Use of  
Medication-Assisted 
Treatment in 
Criminal Justice Settings 
In 2017, the opioid crisis was declared a national 
public health emergency. At the time, over 2.1 million 
people in the United States suffered from an opioid 
use disorder (OUD)1, and two out of three drug 
overdose deaths involved opioids.2 Overdose deaths 
from opioids, including prescription opioids, heroin, 
and synthetic opioids like fentanyl, increased nearly 
six-fold since 1999.3
The criminal justice system has felt the impact of this 
epidemic.4, 5 Based on the 2015-2016 National Survey 
on Drug Use and Health (NSDUH), the odds of being 
arrested and becoming involved in the criminal justice 
system increase greatly for persons using opioids, 
from approximately 16 percent for those with no 
past- year opioid use to 52 percent for those suffering 
from a prescription OUD and 77 percent for those 
using heroin.6
Twenty-four to thirty-six percent of individuals with 
a heroin use disorder (over 200,000 individuals) pass 
through American correctional facilities annually, 
and an estimated 17 percent of state prison inmates 
and 19 percent of jail inmates report regularly using 
opioids.7-9  Roughly 30 to 45 percent of inmates report 
suffering from serious withdrawal symptoms or an 
inability to control their use, indicative of severe 
symptoms of drug dependence.9
These prevalence estimates cannot be attributed 
merely to drug possession offenses. Nearly 15 percent 
of state prisoners and jail inmates convicted of violent 
crimes and 40 percent of those convicted of property 
crimes reported committing their offense to support a 
drug addiction.9 Approximately 7 percent of state prison 
and jail inmates were intoxicated on opioids at the time 
of their offense.9
The impact of opioid use on individuals transitioning 
from jail or prison back to the community is 
overwhelmingly negative. Outcomes include higher 
rates of returning to the criminal justice system, harm 
to families, negative public health effects such as the 
transmission of infectious diseases, and death. Within 3 
months of release from custody, 75 percent of formerly 
incarcerated individuals with an OUD relapse to opioid 
use,10, 11 and approximately 40 to 50 percent are arrested 
for a new crime within the first year.10, 12
Drug overdose is a leading cause of death among 
formerly incarcerated individuals.13, 14 Prisoners and 
jail inmates released to the community are between 10 
and 40 times more likely to die of an opioid overdose 
than the general population, especially within the first 
few weeks after reentering society.13-23 Approximately 
17 percent of persons living with HIV or AIDS 
(approximately 155,000 people) passed through U.S. 
correctional facilities in 2006 alone.24
“For people with OUD 
involved with the criminal 
justice system, a lack of 
access to medication-
based treatment leads to 
a greater risk of returning 
to use and overdose after 
they are released from 
incarceration.”
– Medications for Opioid Use Disorders Save Lives,
The National Academies of Sciences, 
Engineering, and Medicine (2019, p. 99)
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Key Definitions
Medication-Assisted Treatment*
Medication-assisted treatment (MAT) is the use of Food 
and Drug Administration (FDA)-approved medication 
for the treatment of a specific substance use disorder in 
combination with clinically indicated behavioral or cognitive-
behavioral counseling and other indicated services. 
Currently, medications are available to treat tobacco, 
alcohol, and OUD, and research is underway to identify 
effective medications for other substances as well. 
This Guide focuses on MAT for OUDs.
The term “medication-assisted treatment” in no way 
suggests medications are less important or less effective 
than behavioral interventions for treating OUDs. In the early 
stages of treatment, when persons are clinically unstable 
and experiencing withdrawal symptoms or drug cravings, 
evidence suggests medication alone may be adequate to 
enhance treatment retention and initiate abstinence from 
illicit opioids.45-47 No justification exists, therefore, 
for denying access to MAT because psychosocial 
services are unavailable or individuals are unwilling to 
avail themselves of those services. Over time, however, 
combining medication with psychosocial counseling 
appears to produce greater and more sustained 
improvements on important “secondary” or distal outcomes, 
such as reductions in crime and health risk behaviors.48-51 
Therefore, combining medication with psychosocial 
counseling is the recommended best practice for 
treating OUDs.
Criminal Justice 
Criminal justice is a process typically beginning with an 
initial encounter with law enforcement and potentially 
ending with the release of a convicted individual from 
correctional supervision. The criminal justice system 
includes all public entities and government-contracted 
service providers involved in the criminal justice process, 
including police, judges, prosecutors, defense attorneys, 
jail and prison staff, probation and parole officers, and 
contracted service providers such as substance use 
counselors or mental health practitioners.
Probation
A criminal sentence enabling an individual to be supervised 
in the community rather than being incarcerated in jail 
or prison.
Parole
A conditional release from jail or prison allowing an inmate 
to serve the remainder of his or her sentence under 
community supervision.
Prison
A correctional institution run by a state or federal 
government agency or government-contracted provider 
that typically houses individuals serving sentences of 
longer than one year.
Jail
A correctional institution run by a county or state 
government that houses individuals being held in pretrial 
detention or sentenced to less than one year.
Treatment Court
A special court docket or calendar serving persons charged 
with crimes caused or influenced by a mental health or 
substance use disorder or other serious social service 
needs. Participants may enter the program as a condition 
of pretrial supervision, probation, or parole, and successful 
completion of treatment typically leads to the criminal 
charge(s) being dropped or a reduced sentence. Common 
examples include drug courts, mental health courts, and 
veterans’ treatment courts.
Medically Supported Withdrawal 
(Medical Detoxification)
Medically supported withdrawal is a medical procedure 
designed to alleviate acute physiological effects of 
opioids or other substances while minimizing withdrawal 
discomfort, cravings, and other symptoms. Individuals 
may be administered methadone or buprenorphine in 
steadily decreasing doses over roughly 1 to 3 weeks. Other 
medications, such as clonidine, trazodone, or ibuprofen 
may also be prescribed for associated symptoms of 
autonomic hyperarousal (e.g., anxiety, heart palpitations), 
insomnia, or pain, respectively. Relapse rates are extremely 
high after medically supported withdrawal alone; therefore, 
medically supported withdrawal should always be followed 
by a formal course of substance use treatment.47, 52, 53
Maintenance Treatment
Maintenance treatment refers to one type of MAT in which 
people are treated with methadone or buprenorphine for 
several months, for years, or indefinitely. Individuals are 
administered gradually increasing doses of the medication 
until they lack withdrawal symptoms and cravings 
without experiencing intoxication or sedation. Properly 
treated individuals can engage safely and effectively in 
employment, childcare, and other daily living activities. 
According to the U.S. Surgeon General, successful 
maintenance regimens typically last for at least 3 years.52 
*It is important to note that the terminology used in reference to this approach to treatment has been evolving over time. 
For example, the National Academies of Sciences, Engineering and Medicine report uses the term “medication-based 
treatment.” For the purposes of this document, the term “medication-assisted treatment” is used throughout.
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Medication-assisted treatment (MAT) has been carefully 
studied and shown to be effective in treating OUDs.25, 26, 53 
As is discussed in the next chapter, numerous studies 
support the use of MAT for effectively addressing OUDs 
and its negative consequences among criminal justice 
involved persons.27-30
Yet, despite the overwhelming evidence of effectiveness, 
few jails or prisons offer this treatment.9, 25, 31 A national 
study in 2009 found that 86 percent of state and federal 
prisons in the U.S. failed to provide buprenorphine, and 
45 percent failed to provide methadone.32 Of those that 
did provide methadone or buprenorphine, more than half 
offered it exclusively for pregnant women or for chronic 
pain management.5, 32 From 2007 to 2009, less than 1 
percent of state prison and jail inmates with moderate 
to severe substance use disorders received any medically 
supported withdrawal or maintenance services while 
in custody.9
Research conducted more recently in 2018 by the Pew 
Charitable Trusts determined that only 14 states or 
territories in the U.S. (27 percent of jurisdictions) 
offered methadone or buprenorphine maintenance in any 
of their jail or prison facilities, 39 (76 percent) offered
injectable naltrexone as a preventative measure prior 
to release, and only one state (Rhode Island) offered 
all three FDA-approved medications for OUDs.33 
Studies have similarly reported gross underutilization 
of MAT in community corrections programs, such 
as probation, parole, and treatment courts,34-36 as 
well as non-criminal justice treatment programs.37-40 
Several studies found that only about 2 to 10 percent 
of persons with OUDs on probation or parole 
received MAT.41-44
Efforts are rarely made to ensure that returning 
jail or prison inmates have access to this evidence- 
based treatment when they transition back into the 
community.41,44 Less than half of state and federal 
prisons in 2009 referred inmates for methadone 
maintenance after release, and less than one-third 
provided referrals for buprenorphine.32
This Guide focuses on the use of MAT in jails, 
prisons, and the reentry process, when justice-
involved individuals return to the community. 
Reentry may occur through the parole system or 
other mechanisms for releasing individuals from 
custody with ongoing conditions for supervision 
and treatment.
Criminal Justice Involvement Among Adults in the United States 
with Varying Levels of Opioid Use, 2015-2016
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The Opioid 
Epidemic
Historians have tied the opioid epidemic 
in the U.S. to three primary causes:
1   A significant rise in opioid analgesic 
prescriptions that began in the 
1990s, and subsequent increase 
in demand due to widespread 
diversion, misuse, and addiction.  
2   A lack of healthcare provider 
capacity to provide individuals with 
high quality, evidence-based opioid 
use treatment.54
3   A significant increase in the potency 
of illicit opioids, including infiltration 
of fentanyl and other potent 
synthetic compounds into heroin. 
Wave 1
1999 
Prescription opioid overdose deaths 
began to rise as a result of over-
prescribing in the 1990’s. 
Wave 2
2010 
A rapid increase in overdose deaths 
involving heroin began. Deaths from 
prescription opioids reached a new peak.
Wave 3
2013 
Illicitly-manufactured fentanyl and other 
synthetic opioids led to another significant 
rise in overdose deaths.
Source: Centers for Disease Control and Prevention. 
(2018). Understanding the epidemic.  
https://www.cdc.gov/drugoverdose/epidemic/
index.html
Medications Used in  
Medication-Assisted  
Treatment
Three generic medications have been approved by the 
U.S. FDA to treat OUDs: methadone, buprenorphine, 
and naltrexone.53
Methadone
Methadone is a full agonist medication that binds 
preferentially to mu opioid receptors in the brain, thus 
substantially blocking the effects of illicit opioids like heroin.55 
It reduces withdrawal symptoms and cravings for opioids by 
stimulating the receptors, but the effects are gradual and slow 
acting and elicit rapid tolerance to intoxication. Delivered in 
the proper dosage to a person who is physiologically tolerant 
to opioids, there is no experience of intoxication, euphoria or 
sedation, and most people can perform daily tasks safely and 
effectively, including childcare, many types of employment, 
and other nonhazardous activities.
Because methadone is an opioid, it causes physiological 
dependence, can be intoxicating in nontolerant individuals, 
and can cause serious side effects including respiratory 
suppression. Most serious side effects will occur, if at all, 
within the first 2 weeks of methadone treatment, after 
which the risk of overdose is significantly lower than for 
untreated individuals.47
When used to treat OUDs, methadone must be prescribed and 
dispensed from a federally regulated opioid treatment program 
(OTP); however, individuals may receive limited take-home 
doses after meeting specified requirements for treatment 
attendance, clinical stability, and drug abstinence. Methadone 
is typically dispensed in liquid form mixed with juice but is 
also available as a pill.
Naltrexone
Naltrexone is a full antagonist medication that binds 
preferentially to opioid receptors in the brain but does 
not stimulate those receptors. As such, it does not cause 
physiological dependence, intoxication, or serious side 
effects such as respiratory suppression.56
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Naltrexone in pill form is commonly marketed under 
the brand names Revia or Depade. An extended-
release injectable version, Vivitrol, is FDA-approved 
for treating opioid and alcohol use disorders, and 
the effects last for approximately 28 days. It is also 
available as a subdermal (under the skin) implant; 
however, the implant is not FDA-approved in the 
United States.
Naltrexone does not alleviate withdrawal symptoms; 
in fact, administration of naltrexone will precipitate 
withdrawal in persons who are not already detoxified 
from opioids. Although the oral formulation has no 
proven effects for reducing opioid cravings, Vivitrol 
was reported to reduce cravings in randomized trials 
conducted outside of the criminal justice system.57-59 
Naltrexone does not require special licensure or 
certification to administer and may be prescribed 
or dispensed by any licensed medical practitioner 
or pharmacist.
Buprenorphine
Buprenorphine is referred to as a partial agonist 
or mixed agonist-antagonist because it partially 
stimulates opioid receptors in the brain while also 
producing some blockade effects.60 It effectively treats 
withdrawal symptoms and cravings but is less likely 
than methadone to cause intoxication or dangerous side 
effects such as respiratory suppression. Buprenorphine 
is an opioid that elicits physiological dependence and 
can be intoxicating in nontolerant individuals. 
Buprenorphine is marketed under the brand names 
Subutex, Suboxone, Zubsolv, Bunavail, Butrans, 
Buprenex, Probuphine, or Sublocade. It is commonly 
administered as a pill or buccal film that must be 
dissolved sublingually (under the tongue) or attached 
to the cheek. It may be combined with another 
medication, naloxone, which is pharmacologically 
comparable to naltrexone but far shorter acting. If 
a person tries to inject the medication to experience 
an intoxicating effect, the naloxone will be released 
and precipitate withdrawal. This combination has 
been proven to significantly reduce the likelihood of 
inappropriate usage.47 Buprenorphine is also available 
as a monthly injection or subdermal implant that lasts 
for approximately 6 months, and the effects appear to 
be comparable or superior to the oral formulations.61, 62
Buprenorphine may be prescribed and dispensed 
outside of a licensed OTP by physicians or other 
qualified medical practitioners (nurse practitioners, 
physician assistants) who have completed a requisite 
training course and received accreditation referred to as 
a DATA-2000 Waiver.
Overdose Reversal
The FDA has approved another medication, naloxone 
(Narcan), to reverse opioid overdoses and prevent 
overdose death.63 Naloxone is pharmacologically 
comparable to naltrexone; however, its effects are 
far shorter-lasting. It begins to work within 2 to 5 
minutes and lasts for approximately 30 to 60 minutes. 
For some people, multiple doses may be required 
because the duration of action is so much shorter than 
that of opioids. The short duration of action makes it 
unsuitable as a treatment option for addiction, but it can 
have lifesaving effects in medical emergencies. 
Naloxone may be delivered via injection by trained 
professionals or intranasally by nonmedically 
trained laypersons. Studies confirm that educating 
at-risk persons, their significant others, and other 
first responders about naloxone and other overdose 
countermeasures significantly reduces overdose 
deaths.64, 65 Virtually all states shield professional 
first responders from criminal or civil liability if they 
administer naloxone or render comparable medical 
aid in the event of a drug overdose, and many 
shield nonprofessional Good Samaritans as well.66 
Implementing naloxone access laws and protections 
for Good Samaritans has been associated with a 
15 percent decrease in overdose mortality rates.67 
Economic Costs
The Council of Economic Advisors to the White House 
estimated that the economic cost of the opioid crisis 
is $504.0 billion.68
The average annual cost per person of incarceration in 
U.S. prisons dwarfs the per-person cost of methadone 
maintenance treatment—approximately $24,000 versus 
$4,700 annually per person.69
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Availability of Medication-Assisted Treatment within 
the Criminal Justice System
Despite the substantial evidence supporting MAT for the treatment of OUDs, few jails or prisons offer this treatment. 
Moreover, upon release or diversion from the criminal justice system, most individuals with severe OUDs are not 
connected with MAT services in the community.
In Jails and Prisons 
30 out of 5,100
prisons and jails in the U.S. offered methadone or 
buprenorphine in 2017.70
14
states offered methadone or buprenorphine maintenance 
for jail or prison inmates in 2018.33
In Drug Courts
80%
In a 2018 study, participants with 
OUDs were 80% less likely to 
graduate from drug court.71
 50% 
Approximately 50% of drug courts required 
participants to discontinue methadone or 
buprenorphine within 30 days in a 2017 study.72
 50% 
< 50% of drug court participants with 
OUDs received MAT in a 2018 study.73
Upon Reentry or Community Corrections
45%
of state and federal 
prisons in the U.S. 
referred inmates 
for methadone 
maintenance after 
release in 2009.32
 29%
of state and federal 
prisons in the U.S. 
provided referrals 
for community 
buprenorphine 
providers in 2009.32 
Without MAT, there was a 
10-40x higher
 R ISK OF DEATH
from overdose within two 
weeks of release from 
prison in a 2018 study.23
    
<5%
of persons with OUDs referred to 
treatment in 2014 by probation, 
parole or court authorities received 
methadone or buprenorphine 
compared to 41% referred by non-
criminal justice sources.74
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Methadone Buprenorphine 
 
Naltrexone 
Extended-release 
Naltrexone (Vivitrol)
How  
it's taken
Tablet or liquid Tablet, film, or extended-
release injection or implant
Tablet Injection, usually in 
the buttocks
What  
it does
Relieves withdrawal 
symptoms and cravings 
by stimulating opioid 
receptors in the brain. 
Methadone binds 
preferentially to mu opioid 
receptors and may reduce 
the effects of other illicit 
opioids such as heroin. 
Delivered in the right dose 
to a person tolerant to 
opioids, it does not cause 
intoxication, euphoria, 
or sedation, and most 
people can perform most 
daily tasks. Because 
methadone is an opioid, 
it is addictive and can 
cause serious side effects 
including respiratory 
depression and death. 
Because it can cause 
intoxication in nontolerant 
individuals, it may also be 
sold or traded illegally.
Like methadone, 
buprenorphine relieves 
withdrawal symptoms and 
cravings by stimulating 
mu opioid receptors in 
the brain. It, too, binds 
preferentially to these 
receptors, and may 
diminish the effects of 
illicit opioids. It is referred 
to as a mu opioid partial-
agonist because it exhibits 
a ceiling effect such that 
dangerous side effects of 
full mu opioid agonists, for 
example methadone, such 
as respiratory depression 
do not occur.
If a person taking 
naltrexone uses 
opioids, naltrexone 
blocks the euphoric 
and sedative effects of 
the drug. Naltrexone 
binds preferentially 
to opioid receptors in 
the brain but does not 
stimulate the receptors. 
It is not an opioid and is 
neither intoxicating nor 
addictive. It does not have 
demonstrated effects on 
withdrawal symptoms or 
cravings.
Binds preferentially 
to opioid receptors in 
the brain but does not 
stimulate the receptors. 
The effects last for 
approximately 28 days. 
It is not an opioid and is 
neither intoxicating nor 
addictive. Although oral 
naltrexone has no proven 
effects for reducing opioid 
cravings, the injectable 
extended-release version 
has been shown to reduce 
cravings significantly.
Who can 
prescribe or 
administer it
When used to treat 
substance use disorders, 
methadone may only be 
administered by qualified 
medical providers in 
certified OTPs. Prisons 
and jails can become 
certified OTPs or contract 
with community- based 
OTPs.
Qualified providers who 
meet all requirements 
as defined by the United 
States Code, Code of 
Federal Regulations, and 
other relevant legislation.*
Physicians, nurses, 
physician assistants, 
or pharmacists.
Physicians, nurses, 
physician assistants, 
or pharmacists.
*As defined in 21 U.S.C. § 823(g), as amended by the Drug Addiction Treatment Act of 2000., nurse practitioners, or physician assistants who satisfy the 
definition of a “qualifying other practitioner” under 21 U.S.C. § 823(g)(2)(G)(iv), as amended by the Comprehensive Addiction and Recovery Act of 2016 and 
who have completed an 8 to 24-hour training course and received a waiver pursuant to the Drug Addiction Treatment Act of 2000 (DATA-2000) and Clinical 
Nurse Specialist, Certified Registered Nurse Anesthetist, or Certified Nurse Midwife who satisfy the definition of a “qualifying other practitioner” under 21 U.S.C. 
§ 823(g)(2)(G)(iv), as amended by the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and 
Communities Act of 2018, until October 1, 2023. Implementation of this provision of the SUPPORT for Patients and Communities Act is in process. For more 
information, please go to SAMHSA’s website.
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Why Is It So Difficult to Incorporate Medication-Assisted 
Treatment into the Criminal Justice System?
Despite the overwhelming evidence in support of MAT, as discussed in the next chapter, there are various reasons it is 
underutilized within the criminal justice system.25, 31, 35, 36, 38, 39, 44, 47, 52, 70, 73, 75 Understanding these challenges is essential for 
overcoming the barriers.
1 Misunderstanding or  
Lack of Information
Some of the reluctance of criminal justice 
leadership to adopt MAT comes from a 
misunderstanding of MAT and the mechanisms 
by which the medications work. Some officials 
and practitioners view these medications as 
replacing one addictive drug for another.75 Others 
believe that forced withdrawal from opioids is 
part of living “a clean lifestyle.”32, 44
2 Current Policies Do Not Support MAT
Some jails and prisons have policies that prohibit 
the use of controlled substances (including the 
medications used in MAT).7 Some drug courts 
may require detoxification from methadone or 
buprenorphine treatment as a condition 
of participation.7
3 No Trained Providers
Some jails and prisons do not have the capacity 
to treat substance use disorders in their facilities.76 
Individuals already on MAT may be forced to 
disrupt treatment upon incarceration, leading to 
physiological and psychological problems.7 Some 
jails and prisons will arrange for a community-
based provider to provide MAT. However, many 
facilities do not have trained medical personnel 
available.31, 77, 78
4 Medically Supported Withdrawal 
Services Available, but No 
Maintenance Therapy 
Some criminal justice facilities will offer 
short-term MAT to detoxify individuals from 
opioids. However, when only medically 
supported withdrawal is provided to incarcerated 
individuals, rates of post-release overdose and 
death are high.7 Jails and prisons may only 
provide methadone maintenance therapy if they 
are registered with the U.S. Drug Enforcement 
Agency as an OTP.79 SAMHSA and state opioid 
treatment authorities may also certify jails and 
prisons as OTPs. 
Many correctional facilities do not have the 
personnel, capacity, or desire to register as an 
OTP.7 Jails and prisons may also make methadone 
accessible to inmates without having to become 
certified as OTPs through agreements with 
community-based OTPs. This would allow 
methadone to be securely transported to a 
facility from an OTP or enable inmates to be 
transported to a community-based OTP for 
dosing. More information about these options 
can be found in the Federal Guidelines for Opioid 
Treatment Programs.
5 Concerns About Security and Liability
Concerns about security and the risk of diversion 
cause some jails and drug courts to either limit or 
deny access to buprenorphine or methadone.7, 32, 
35, 44 Diversion, misuse, and potential overdose are 
also liability concerns for some courts.44 
As discussed in Chapter 4, these concerns can be 
addressed safely and effectively in most programs.
6 Costs of MAT
Buprenorphine or methadone may not be offered 
in prisons and drug courts because of cost 
concerns and insufficient funding.35, 44 Strategies 
for obtaining funding are described in Chapter 4. 
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Promising Programs and Practices That Support the 
Use of Medication-Assisted Treatment
There are several promising practices that have been used within criminal justice settings and during transition into the 
community that can facilitate successful outcomes.
Partner with 
Community Providers
Correctional facilities can develop 
partnerships with registered opioid 
treatment programs and other providers 
of MAT. Incorporating jails and prisons 
into a system of care allows incarcerated 
individuals to continue MAT upon 
incarceration and/or to connect with MAT 
services once they reenter the community.
Embed MAT Within 
Drug Court Programs
Many drug courts do not 
recommend (or even allow) the use 
of MAT for opioid dependence.80 
Approximately half of drug courts 
surveyed in one study offered any 
form of MAT to participants.35
Ensure Linkages 
to Treatment
According to a 2009 publication, 
only 45 percent of criminal justice 
facilities provided any community 
linkages to methadone treatment 
clinics.32 Treatment with MAT and 
brief drug counseling integrated into 
the probation and parole system have 
shown positive results in terms of 
opioid use and re-arrest rates.28, 30, 43, 81
Support Police Officer-led 
Diversion Programs
Some police departments have engaged 
in training their officers to identify and 
divert non-violent opioid dependent 
individuals into MAT programs. One 
such program is the Law Enforcement 
Assisted Diversion (LEAD) Program in 
Seattle, Washington.82
Change Organizational 
Policies to Reflect the Science 
Based on the overwhelming evidence 
base for MAT, many jails, prisons, parole, 
probation, and diversion programs are 
changing policies that prohibit the use of 
MAT medications. A growing number 
of states have enacted legislation 
authorizing or requiring expansion of 
MAT in the criminal justice system.83 
Register as a 
MAT Provider 
Some jails and prisons have 
registered to become an opioid 
treatment program or have medical 
staff obtain buprenorphine waivers. 
For example, the Key Extended 
Entry Program (KEEP) is a methadone 
treatment program initiated in 
1987 for incarcerated individuals. 
KEEP participants receive MAT behind 
bars, and when returning into the 
community, they are discharged to 
outpatient KEEP programs.84
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C H A P T E R
WHAT RESEARCH TELLS US
Effectiveness of 
Medication-Assisted 
Treatment in Criminal 
Justice Settings
There is overwhelming evidence that medication- 
assisted treatment (MAT) is an effective intervention 
for addressing opioid use disorders (OUDs) in criminal 
justice and non-criminal justice populations. Several 
meta-analyses and systematic reviews have focused 
specifically on its effects in probation, parole, jail, and 
prison settings.1-11 
This chapter focuses primarily on the evidence base for 
the use of MAT with jail and prison populations and in 
community reentry after release. 
Withdrawal and Cravings
Pharmacological benefits derived from the medications 
are well studied and well understood. Methadone 
and buprenorphine alleviate withdrawal symptoms 
and cravings for opioids by stimulating mu opioid 
nerve receptors in the brain.12-15 Because they bind 
preferentially to the receptors, they can diminish the 
effects of illicit opioids that may be used such as heroin.
A person who is physiologically tolerant to opioids will 
not experience intoxication, euphoria, or sedation when 
receiving these medications in the proper dosage, and 
most people can safely and effectively perform daily 
tasks, including childcare, many types of employment, 
and other nonhazardous activities.
Within this chapter, ratings are provided to 
indicate which outcomes are associated 
with the use of methadone, buprenorphine, 
oral naltrexone, and extended release (XR) 
naltrexone within the criminal justice system.
This chapter uses a three-tiered rating 
system for the evidence.
R  Reliable benefits
Effectiveness reported in at least two 
meta-analyses, systematic reviews, or 
randomized controlled trials conducted in 
criminal justice populations. 
P  Potential benefits
Effectiveness reported in randomized 
experiments conducted outside of the criminal 
justice system or in correlational studies 
involving justice-involved persons.
U  
 
Unproven benefits
Insufficient testing or unproven effectiveness.
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Naltrexone, in contrast, binds preferentially to 
opioid receptors in the brain but does not stimulate 
those receptors.14, 16, 17 As such, it does not reduce 
withdrawal symptoms; in fact, introduction of 
naltrexone will precipitate withdrawal for persons who 
have not already been withdrawn from opioids. Oral 
naltrexone has no proven effects for reducing opioid 
cravings.18 However, the extended-release formulation 
has been shown to reduce cravings in randomized 
trials and brain-imaging studies conducted outside of 
the criminal justice system.19-22
Withdrawal:
RPU
Methadone
RPU
Buprenorphine 
RPU
Oral Naltrexone 
RPU
XR-Naltrexone 
Cravings:
RPU
Methadone
RPU
Buprenorphine 
RPU
Oral Naltrexone 
RPU
XR-Naltrexone 
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Treatment Entry 
and Retention
Methadone and buprenorphine are reliably proven to 
increase entry into and retention in treatment during 
incarceration and after release to the community.7, 9, 11 
In contrast, meta-analyses have reported mixed or 
nonsignificant effects of oral and extended-release 
naltrexone on treatment entry and retention in criminal 
justice populations.1, 7 Observational reports in a few 
studies with methodological weaknesses suggest the 
extended-release formulation may potentially enhance 
treatment engagement among probationers or parolees 
in community-based settings;23, 24 however, these 
findings must be replicated in better controlled studies.
RPU
Methadone
RPU
Buprenorphine 
RPU
Oral Naltrexone 
RPU
XR-Naltrexone 
Illicit Opioid Use
Methadone, buprenorphine, and extended-release 
naltrexone have been reliably demonstrated to reduce 
illicit opioid use in studies involving jail, prison, 
probation, and parole populations.1, 2, 7 Much of the 
support for buprenorphine comes from head-to-head 
comparisons with methadone in which drug use 
outcomes were determined to be equivalent.7, 25, 26 
Although oral naltrexone was found in one 
randomized experiment to significantly reduce opioid-
positive drug tests among federal probationers,27 most 
studies have failed to find significant effects on drug 
use, largely as a result of poor medication compliance 
and high treatment dropout rates.28-30
RPU
Methadone
RPU
Buprenorphine 
RPU
Oral Naltrexone 
RPU
XR-Naltrexone 
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Criminal Recidivism
Studies employing suitable comparison groups 
have not found reliable effects from methadone 
or buprenorphine on criminal justice outcomes, 
including re-arrest rates, re-conviction rates, 
reincarceration rates, or self-reported criminal 
activity.3-8, 10, 11 Nevertheless, retention in 
methadone or buprenorphine treatment is often 
correlated with significantly lower rates of criminal 
activity.31-35 This finding suggests that methadone 
or buprenorphine may elicit indirect effects on 
crime by enhancing treatment engagement and 
reducing illicit opioid use. 
Further studies are needed to determine whether 
increasing retention and adherence in methadone or 
buprenorphine treatment leads to more consistent 
improvements in criminal justice outcomes.
The effects of naltrexone on criminal recidivism 
have been more promising, but mixed. Four meta- 
analyses reported significant reductions in re-arrest 
or reincarceration rates for naltrexone without 
differentiating between delivery in the form of 
pills, extended-release injections, or implants.1-3, 8
However, a 2019 meta-analysis concluded that too 
few studies employing adequate methodologies 
have been conducted to reach firm conclusions 
about the effects on crime.7 A recent multi-site 
randomized controlled trial found no effects of 
injectable naltrexone on re-arrest rates, average 
numbers of re-arrests, or average time to the 
first new arrest over an approximately 18-month 
follow-up period.36 Additional research is needed 
to determine whether naltrexone produces reliable 
effects on crime, and whether enhancing adherence 
to naltrexone regimens leads to greater reductions 
in criminal recidivism.
RPU
Methadone
RPU
Buprenorphine 
RPU
Oral Naltrexone 
RPU
XR-Naltrexone 
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Overdose Risk 
Studies employing equivalent comparison groups 
have not found reliable effects from administering 
methadone or buprenorphine during incarceration 
on post-release overdose rates.7, 10 However, strong 
correlational evidence indicates that providing 
methadone or buprenorphine both during custody 
and after release to the community is associated with 
substantially lower rates of opioid overdose and 
mortality.9, 33, 37-41
Significant reductions in mortality have only been 
observed when participants received methadone or 
buprenorphine beginning in custody and continuing 
for at least four consecutive weeks after release to the 
community.39, 42 Any protective effects that might be 
achieved from prison or jail-based treatment appear 
to degrade quickly if methadone or buprenorphine are 
not delivered continuously in the community. 
Further studies using better experimental designs are 
needed to confirm whether providing methadone or 
buprenorphine during and after release from custody 
reliably reduces opioid overdose and death rates. 
Comparatively less research has examined the effects 
of naltrexone on opioid overdose and mortality 
rates. Two recent meta-analyses concluded there 
were too few studies to estimate an effect size on 
overdose rates.7, 43 However, a multi-site randomized 
controlled trial reported a significantly lower overdose 
rate for participants on community-based criminal 
justice supervision receiving injectable naltrexone.44 
Additional studies are needed to replicate this finding 
and determine how best to administer naltrexone to 
reduce opioid overdose and mortality rates
RPU
Methadone
RPU
Buprenorphine 
RPU
Oral Naltrexone 
RPU
XR-Naltrexone 
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Health Risk Behaviors  
Relatively few studies have examined the effects of MAT 
on other health risk behaviors commonly observed among 
persons with OUDs in the criminal justice system, such as 
syringe sharing or unprotected sex with multiple sex partners. 
Correlational evidence suggests that provision of methadone 
during custody and after release to the community is associated 
with significantly lower rates of injection drug use and 
contraction of communicable diseases.7, 9, 33 
Meta-analyses have also concluded that combining methadone 
with psychosocial counseling designed to reduce health risk 
behaviors significantly reduced syringe sharing, sexual risk 
behaviors and contraction of communicable diseases among 
recently released jail and prison inmates.45, 46  Less research 
has examined the effects of buprenorphine or naltrexone on 
health risk behaviors. One randomized experiment conducted 
outside of the criminal justice system found significantly lower 
rates of self-reported HIV risk behaviors for persons receiving 
injectable naltrexone.20 More research is needed to confirm the 
effects of MAT on health risk behaviors associated with opioid 
use and determine what additional psychosocial interventions 
are needed to augment or maintain them.
RPU
Methadone
RPU
Buprenorphine 
RPU
Oral Naltrexone 
RPU
XR-Naltrexone 
Which Medication 
is Better?
Head-to-head comparisons between the 
medications have been largely inconclusive. 
A few studies conducted in the criminal justice 
system found no differences in opioid-use 
outcomes when methadone was compared 
against buprenorphine or extended-release (XR) 
naltrexone.8, 25, 47 Studies conducted outside 
of the criminal justice system have similarly 
found no differences in drug use outcomes 
for buprenorphine versus methadone26 or XR-
naltrexone.19, 22
Some evidence suggests methadone may be 
superior to buprenorphine for retaining people 
longer in treatment.26, 48 However, studies 
conducted in the criminal justice system have 
not reported this finding.25, 49 Studies comparing 
XR-naltrexone to buprenorphine outside of the 
criminal justice system have reported mixed 
effects on treatment entry and retention. One 
experimental study reported equivalent retention 
in treatment,19 whereas another found that 
significantly fewer participants began treatment 
with XR-naltrexone.22
Differences in the benefit profiles of the 
medications might suggest—but are by no means 
conclusive—that methadone or buprenorphine 
may be more effective than naltrexone for 
retaining persons suffering from severe 
withdrawal symptoms in treatment, whereas XR-
naltrexone may be more effective for reducing 
crime among those at high risk for recidivism. 
Lacking any direct evidence to support such 
matching effects, these are hypotheses that must 
be tested in controlled studies.
Evidence does suggest that if a person is not 
responding adequately to one of the medications, 
changing the regimen can lead to more effective 
outcomes. One study conducted outside of the 
criminal justice system found that individuals not 
responding to buprenorphine could be switched 
effectively to methadone.50
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Choice of Medications
Medical practitioners must take a multitude 
of factors into account when deciding which 
medication to use in a given case. The likelihood of 
therapeutic success and dangerous side effects can 
be influenced by a host of variables. These include, 
but are not limited to, the following:51 
■ person’s medication preference 
and motivation for change
■ age at onset, duration, and severity 
of opioid use
■ other substances, if any, used in 
conjunction with opioids
■ co-occurring psychiatric or medical 
conditions, if any
■ prior history of and response to substance 
use disorder treatment 
■ prior history of and response to MAT
■ family history of mental health and/or 
substance use conditions
■ other prescription medications being 
taken by the person
Non-medically trained criminal 
justice professionals should never make 
medication decisions related to MAT.52, 53
Overlooking these factors and selecting the wrong 
medication can have dire consequences, including an 
unwarranted risk of dangerous medication reactions, 
treatment dropout, and overdose death. 
Blanket prohibitions against MAT or against certain 
medications, such as methadone or buprenorphine, 
are medically unjustified and potentially harmful. 
Requiring inmates to discontinue or change a 
medication regimen that was previously successful is 
associated with poor outcomes and a lower likelihood 
of resuming MAT after release from custody.54 Worse, 
because physiological tolerance to opioids declines 
during forced abstinence or while taking naltrexone, 
inmates required to withdraw involuntarily from 
methadone or buprenorphine face a substantially 
increased risk of overdose and death if they 
discontinue treatment upon release and resume illicit 
opioid use.37, 48
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Best Practices for 
Medication-Assisted 
Treatment in the Criminal 
Justice System 
Several practices have been reliably associated with 
positive MAT outcomes in criminal justice and non- 
criminal justice populations. Failure to abide by these 
practices can undermine the effectiveness of MAT and 
worsen outcomes.
   
Counseling and Social Services 
The importance of psychosocial counseling in 
treating OUDs appears to be a matter of timing. 
In the early stages of treatment, when individuals 
are clinically unstable and experiencing 
withdrawal symptoms or drug cravings, 
medication alone may be adequate to enhance 
treatment retention and initiate abstinence from 
illicit opioids.48, 55, 56
Several studies in community-based OTPs 
and physician practices found no incremental 
benefits from adding evidence-based counseling 
to MAT on treatment retention or illicit 
opioid use during the first 3 to 12 months of 
treatment.57-60 No justification exists, therefore, 
for denying access to MAT because psychosocial 
services are unavailable, or individuals are 
unwilling to avail themselves of those services. 
For many individuals, MAT alone may be 
enough to begin them on the road to recovery.
For most people, however, MAT alone is 
unlikely to produce sustained recovery or 
healthy adaptive functioning over the long run. 
Approximately 35-75 percent of individuals, 
including those involved in the criminal justice 
system, discontinue methadone, buprenorphine 
or naltrexone within the first year of treatment, 
often within the first few months.48, 61-63 
Counseling is needed, therefore, to maintain 
persons’ initial motivation for change and assist 
them in identifying and resolving barriers to 
treatment adherence.48
As reviewed earlier, more research is needed 
to understand whether MAT produces 
demonstrable effects in criminal justice 
populations on important “secondary” or distal 
outcomes, including criminal and health risk 
behaviors. Combining MAT with psychosocial 
counseling produces larger and more sustained 
effects in these critically important psychosocial 
domains.45, 46, 64-67 Unfortunately, little is known 
about which types of psychosocial interventions 
produce better outcomes in combination with 
MAT, and when they should be introduced in the 
course of treatment.66  
No justification exists for denying access 
to MAT because psychosocial services are 
unavailable or individuals are unwilling to avail 
themselves of those services.
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Medication Dosage 
Institutional policies limiting the dosage or 
duration of MAT are unwarranted and likely to 
undermine treatment effectiveness. Like any 
medication, methadone, buprenorphine, and 
naltrexone must be delivered in an adequate 
dosage and for a long enough time to achieve 
the desired pharmacological effects. Some 
studies in jails and prisons have reported 
average methadone doses of approximately 
30 to 50 mg per day over brief intervals of a 
few weeks to about 6 months; however, 
significant improvements have typically only 
been reported when doses exceeded 60 mg 
(and often higher than that) over several months 
to more than a year.9, 48
   
Medication Duration 
and Tapering 
Evidence is clear that long-term or indefinite 
treatment with medications for OUDs is often 
required for effective and sustained outcomes.48 
In practice, successful tapers from methadone or 
buprenorphine typically occur in only about 15 
percent of cases, the likely result of premature or 
unwarranted discontinuation of the medication 
regimens.51, 68 Administering MAT for 90 days or 
less, which is common practice in many jails and 
prisons, offers no beneficial effects.51 According 
to the U.S. Surgeon General, successful tapers 
typically occur, if at all, when individuals have 
been treated with MAT for at least 3 years.69
Certain clinical benchmarks for success should 
be reached before considering a medication 
taper. Evidence in general community treatment 
settings suggests that individuals should be 
abstinent from all illicit drugs and alcohol and 
stable with respect to their physical and mental 
health, vocational and educational needs, and 
family problems for at least one to two years 
before beginning to taper a methadone or 
buprenorphine regimen.64, 70-72
 
Because naltrexone is nonaddictive and has 
 relatively minimal side ef fects, fewer concerns 
are commonly expressed about tapering a 
naltrexone regimen. Some experts recommend 
maintaining individuals on naltrexone for at 
least one year;17, 73 however, some have been 
treated successfully on naltrexone for at least 
five years with no negative effects.74
 
Co-Occurring Mental 
 Health Disor ders
Approximately 15-20 percent of individuals on 
probation, parolees, and jail and prison inmates 
suffer from a serious or persistent mental health 
disorder.75, 76 Individuals with mental health 
disorders fail disproportionately on probation 
and parole, and co-occurring mental illness 
interferes significantly with the effectiveness of 
correctional substance use treatment programs.77 
When mental illness is combined with substance 
misuse, the odds of criminal recidivism and 
failure in correctional rehabilitation appear to 
increase multiplicatively.78, 79 
Substance use and mental health disorders are 
reciprocally aggravating conditions, meaning that 
continued symptoms of one disorder are likely to 
precipitate relapse in the other.80, 81 For example, 
a person recovering from drug addiction who 
continues to experience depressive symptoms 
has an elevated risk for relapsing to drug use. 
Conversely, a person recovering from depression 
who continues to use illicit drugs is likely to 
experience a resurgence of depressive symptoms.
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For this reason, co-occurring mental health 
and substance use disorders should be treated 
concurrently as opposed to consecutively.82, 83 
Whenever possible, both disorders should be 
treated in the same facility by an interdisciplinary 
team using an integrated treatment model that 
focuses on the mutually aggravating effects of 
the two conditions. SAMHSA has published 
therapist toolkits to assist in delivering evidence- 
based integrated treatments for co-occurring 
substance use and mental health disorders.84
Participants should also have unhindered 
access to medical providers qualified to 
prescribe and monitor response to psychiatric 
medications and ensure those medications are 
used safely and effectively in combination 
with MAT for OUDs. A statewide study of 
community- based treatment reported that 
use of MAT was associated with significant 
reductions in inpatient substance use treatment 
for individuals with co-occurring disorders 
and use of oral naltrexone was associated 
with significant reductions in inpatient mental 
health days, greater adherence to psychiatric 
medications, and lower re-arrest rates.85
 
Post-Release Services
  
Success after release from custody requires 
the individual to continue receiving MAT, 
counseling, and other indicated services in 
the community.65 Institutional treatment alone 
without follow-up care is rarely successful. 
Worse, because physiological tolerance declines 
if individuals are not maintained on methadone 
or buprenorphine while incarcerated, release to 
the community without follow-up care can lead 
to higher rates of opioid overdose and mortality 
if they return to pre-incarceration levels of 
opioid use.33, 37
The factor that best distinguishes effective from 
ineffective prison and jail-based MAT programs 
is whether participants experience a smooth 
transition to follow-up care while on parole or 
after release to the community.7, 9 Systematic 
reviews of the research literature have concluded 
that significant reductions in criminal recidivism 
and improvements in employment are typically 
observed for post-release reentry programs that 
share at least the following characteristics:86-90
■ Community providers meet with participants 
prior to their release from custody to assess 
their treatment and social-service needs, 
inform them about available community 
services, and develop a transitional treatment 
plan to ensure seamless receipt of indicated 
services after discharge. 
■ Community-based services are delivered 
immediately upon release, are intensive in 
nature (at least 8 hours per week), and last for 
at least six months. 
■ Participants receive at least a four-week supply 
or prescription (and preferably longer) of 
needed medications.
■ Counseling interventions are documented in 
treatment manuals, are behavioral or cognitive-
behavioral in orientation, and are delivered by 
professionally trained service providers. 
■ Participants receive evidence-based housing, 
vocational, and mental health services, where 
indicated.
■ Supervision officers monitor participants’ 
progress, use motivational enhancement 
techniques to increase compliance with 
treatment, reward achievement of treatment 
goals, and administer gradually escalating 
consequences (short of reincarceration) for  
treatment attrition or other infractions that do 
not involve a new criminal offense.
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Preventing Misuse
Criminal justice professionals have an important role 
to play in minimizing misuse of medications. These 
concerns are usually most pressing after participants 
have been released from custody and are taking the 
medications in the community. Several practical 
precautions have been demonstrated empirically to 
reduce untoward events related to MAT.91-94
 
Observed Administration
  
One of the most effective ways to prevent 
misuse or diversion of prescription medications 
is to require the medication to be ingested 
under the direct observation of treatment or 
criminal justice staff. After release from custody, 
ingestion may be observed by a medical staff 
person, probation officer, clinical case manager, 
or other approved individual such as a trusted, 
sober, and prosocial family member or friend.
   
Medication Level Monitoring
The presence of prescribed medications or their 
metabolites may be monitored through urine or 
other appropriate testing methods on a random 
basis to confirm the medication is being  
taken reliably.
 
Pill Counts
  
If take-home doses are permitted, participants 
may be called back on a random basis for pill 
counts to confirm the medication is being taken 
as prescribed. A short pill count may indicate 
the medication is being taken too often or 
in excessive doses or is being sold or traded 
illegally. A high pill count indicates it is not 
being taken as prescribed.
Medication Event Monitoring 
  
A medication event monitoring system 
(MEMS) is a medication vial or cap with a 
microprocessor that records the date and time 
and the number of pills removed each time the 
container is opened. Use of a MEMS provides a 
reliable indicator of appropriate medication use 
among individuals with severe mental health 
disorders.95 However, it has not been evaluated 
in a criminal justice population.
Newer applications designed for smart 
phones or other electronic devices offer more 
sophisticated methods for monitoring and 
enhancing medication adherence. Phone-
based applications, for example, can deliver 
medication reminders and motivational prompts 
and use facial recognition technology to confirm 
ingestion in real time. Studies confirm that use 
of such applications can enhance adherence to 
psychiatric and other medications.96, 97 However, 
these methods need to be examined in criminal 
justice populations.
   
Abuse-Deterrence Formulations
Misuse and diversion of medications has 
been reduced significantly by combining 
buprenorphine with naloxone (which elicits 
withdrawal if the medication is injected), 
administering the long-acting injectable 
formulation of naltrexone, administering 
methadone in liquid form, and administering 
buprenorphine in the form of a soluble 
sublingual film.
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Prescription Drug 
 Monitoring Pr ograms
Prescription drug monitoring programs (PDMPs) 
are state-maintained databases of specified 
medications prescribed within the state and 
other jurisdictions with reporting reciprocity.98 
Reports typically include a list of prescriptions 
for controlled medications filled for a given 
individual within the previous 12 months.
As of April 2019, all U.S. states other than 
Missouri, as well as the District of Columbia, 
Guam and Puerto Rico, had a PDMP. Nearly 
all jurisdictions permit pharmacists, physicians 
and/or other medical practitioners (e.g., nurse 
practitioners) to access PDMP information 
relating to their patients or clients. In addition, 
most states and territories authorize PDMP 
reports to be communicated to law enforcement 
personnel, and approximately one-third authorize 
reports to community corrections agencies or 
drug courts.99 
PDMP monitoring has been shown to reduce the 
incidence of dangerous medication interactions 
by bringing other medications taken by patients 
to the attention of prescribing physicians and 
dispensing pharmacies.100
Statewide studies have found that requiring 
mandatory reporting to PMDPs was associated 
with significant improvements in physician 
prescribing practices, including fewer individuals 
receiving overlapping prescriptions for the same 
opioid, obtaining opioids from five or more 
doctors or pharmacies (“doctor shopping”), 
or receiving refill authorizations of seven or 
more months.101-104 A recent study concluded 
that implementation of mandatory reporting 
to PDMPs was associated with a 3-4 percent 
decrease in overall crime rates and a 5-7 percent 
decrease in violent crime rates.105
Most studies have reported significantly lower 
rates of opioid misuse and opioid-related 
mortality after implementation of mandatory 
PDMPs.106-108 However, a few studies have 
paradoxically reported increased use of heroin 
or other illicit opiates in response to the reduced 
availability of pharmaceutical opioids.109, 110 
Programs should, therefore, monitor participants 
continually for the possible emergence of other 
substances and take suitable measures to address 
the issue should it arise.
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Examples of 
Medication-Assisted 
Treatment Programs 
in Criminal Justice
Settings 
3
C H A P T E R
In this chapter, six programs are highlighted that have 
used medication-assisted treatment (MAT) (utilizing 
buprenorphine, methadone, and/or naltrexone) to treat 
individuals with opioid use disorders (OUDs) in the 
correctional system—within jails, prisons, and on reentry 
to the community. Each of these programs has achieved 
outcomes consistent with the research on the effectiveness 
of MAT in these settings.
There are two basic models for the provision of MAT in 
correctional settings. The first, exemplified by New Jersey 
and Rhode Island, provides the full range of medications 
to treat OUD over a long-term maintenance period. This 
model aims to stabilize individuals over the course of 
their sentences and after release. The second model, 
exemplified by Kentucky and Massachusetts, focuses 
on relapse prevention. Often detoxified upon entry into 
the criminal justice system, individuals with OUDs are 
provided naltrexone immediately before release and for a 
period thereafter to avoid the heightened risk of relapse on 
reentry into the community.
Both of these models appear to be more effective than 
programs that offer no MAT. Since the approaches have 
not been directly compared, there is currently no data 
documenting which model is more effective overall. 
However, based on the outcomes of related research, 
evidence indicates that offering all forms of MAT is likely 
to be more effective in most settings, and where possible, 
offering all forms of MAT is considered best practice.
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Choosing Programs
While there are additional excellent programs that could 
have been featured in this section, the panel of experts 
considers these to be well-delineated and replicable. Each has 
successfully delivered MAT in jails, prisons, or reentry, and 
has reported early evidence of promising results.*
Especially within recent years, varied program models have 
developed across the country. Programs, including those 
highlighted here, are continuously changing and developing 
in response to many factors, including need, population, 
development of the science, and resource availability. These 
programs should not be taken as definitive of best practices in 
service delivery, nor representative of all potential program 
models. Rather, they represent models that have been 
effective in delivering MAT and reported promising outcomes 
in a variety of correctional settings.
It is important to note that the programs represented here were 
chosen in part because they operate in a variety of settings – 
jail, prison, reentry, and combinations thereof. These settings 
present substantially different barriers to treatment, and 
consequently require substantially different service delivery 
practices; therefore, the setting of the programs should be 
taken into account in evaluating and applying the principles 
demonstrated by each model.
Format of the Chapter
Following is a succinct description of each of the six 
programs, including key program components, resources 
needed, cost to operate, and outcomes. The format of these 
one-page documents is uniform to enable readers to quickly 
find the information they seek.
*Although outcomes are reported for each program, not all 
data reported is peer reviewed or verified to as high a standard 
as the data cited elsewhere in this Guide.  Outcome measures 
have been gathered from programs themselves or third party 
research partners, and it should not be assumed that the 
methods or standards cited in this chapter are in any way 
endorsed or verified by SAMHSA.
Use of Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings
Examples of Medication-Assisted Treatment Programs in Criminal Justice Settings 
40
New Jersey
Summary
New Jersey recently increased and improved access to substance 
use disorder treatment in its jails and prisons through several 
initiatives. After its closure in 2014, the Mid-State Correctional 
Facility was reopened in 2017 as an addiction treatment center for 
individuals in prison.1
Corrections (NJDOC) and Human Services (NJDHS), the facility 
now operates as a correctional treatment center, housing nearly 
700 men. Sixty-five additional beds are available for women at 
the Edna Mahan Correctional Facility.2 The program partners 
with Gateway Foundation, a national substance use disorder 
treatment provider, to deliver substance use treatment.3 Although 
the program serves individuals with any alcohol or substance use 
disorder, a primary focus is to address the opioid crisis and its 
criminogenic risk factors. As such, it provides access to evidence- 
based opioid use disorder treatment, including all forms of MAT 
(buprenorphine, methadone, naltrexone).2
The renovation of Mid-State Correctional Facility cost the 
state $28 million, and the state’s partnership with the Gateway 
Foundation includes a provision to cover treatment services for 5 
years at a cost of $29.2 million.2 Several county jails in the state 
have also begun offering MAT. 
91%
Setting Prison
Principles ■■ Accessibility of MAT and 
whole person care
■■ Individualization of treatment
Medications ■■ Buprenorphine
Used ■■ Naltrexone
■■ Methadone
Program Model
On entrance into NJDOC custody, individuals 
are screened for health and substance use 
treatment needs. Those who are classified 
as medium-risk and present with a substance 
use disorder are eligible for the Mid-State 
or Edna Mahan program. Once enrolled, 
individuals are provided with MAT as needed, 
as well as wrap-around services. These 
adjunctive services include counseling, group 
therapy, and health care, provided by Rutgers 
University Correctional Health Care to address 
co-occurring disorders.  In all other aspects, 
Mid-State Correctional Facility functions as a 
medium-security state prison.
The program is individualized based on 
each participant’s needs, with the intensity of 
treatment provided varying from 7 to 28 hours 
per week and lasting as long as necessary for 
recovery. In 2018, a partnership with the New 
Jersey Department of Health (NJDOH) was 
created to facilitate ongoing follow-up services. 
Navigators monitor released participants for 
one year to track progress and connect them 
to reentry and substance use disorder 
treatment providers.
Outcomes4
100
individuals 
across NJDOC have 
received MAT each 
month since November 
2017, according to the 
NJDOC Commissioner.
91 percent of justice-involved 
individuals receiving MAT in 
the state complete treatment 
successfully, compared to 50 
percent of those receiving other 
addiction treatment, according to 
the NJDOH Commissioner.
Rhode Island
Summary
As part of a statewide initiative to address the opioid epidemic, the 
Rhode Island Department of Corrections (RIDOC) implemented a new 
model for treatment within the correctional setting in January 2017. 
RIDOC works through a partnership with CODAC Behavioral Health, 
a community vendor with statewide capacity, to ensure access to MAT 
for individuals with an opioid use disorder (OUD) while in custody. 
All three medications approved to treat OUD by the Food and Drug 
Administration (FDA) (buprenorphine, methadone, naltrexone) are 
offered.5 As a result, Rhode Island is now the only state in the country to 
offer all forms of MAT across their entire incarcerated population.6
To maintain treatment post-release, 12 MAT Centers of Excellence were 
established across the state. They repurposed an existing network of 
CODAC outpatient facilities to continue care for reentering individuals 
in the community. These facilities are scattered throughout the state to 
enable formerly incarcerated individuals to continue treatment regardless 
of their location post-release. To facilitate this transition, incarcerated 
individuals are coached on how to apply for Medicaid prior to release.5
The relationship between RIDOC and CODAC staff is critical to the 
success of the program. CODAC provides medical directors, a project 
coordinator, a program director, three masters/licensed assessment 
clinicians, two MAT clinicians, a discharge planner, and peer support 
specialists to aid in reentry. Although clinical staff are primarily 
responsible for prescribing and dispensing MAT, RIDOC medical and 
nursing staff are also educated on MAT to enable coordination of care. 
$2 million per year is dedicated to the program.7
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Setting Prison; Jail; Reentry
Principles ■■ Continuity of treatment
■■ Access to all forms of MAT 
during incarceration
Medications ■■ Buprenorphine
Used ■■ Naltrexone
■■ Methadone
Program Model
Upon entrance into RIDOC, all individuals are 
screened for substance use disorders and 
other treatment needs. Individuals who screen 
positive for an OUD and are in need of treatment 
are enrolled in the program. Those awaiting 
trial are not withdrawn from MAT, and those 
already receiving medications are maintained 
on their current regimens. During incarceration, 
individuals have access to all FDA-approved 
medications to treat OUD, as well as individual 
and group counseling.7
Originally, programs emphasized group 
counseling similar to an “outpatient format” 
within the correctional setting. RIDOC developed 
a residential treatment model in 1992, in which 
inmates are housed on separate units staffed by 
treatment professionals and peers in sustained 
recovery.  Treatment is now based on a four-tier 
model (listed from highest to lowest level 
of care):
1. Modified residential therapeutic 
community, 
2. Day treatment, 
3. Counseling groups, and 
4. Recovery services/peer support.8
On release, individuals are coached on how 
to apply for Medicaid and are referred to a 
Center of Excellence, which provides treatment 
within the community. These community-based 
services aim to ensure successful reintegration 
and maintain stability. They include continued 
MAT, psychiatric care for co-occurring mental 
health disorders, counseling and education 
for patients and their families, peer recovery 
support, Hepatitis C testing and on-site 
treatment, and reentry services.9
Outcomes**
After the successful implementation of numerous statewide 
initiatives, including the RIDOC program, Rhode Island has seen 
significant reductions in overdose rates.5
**Green et al. (2018) acknowledge 
a small sample size as a limitation 
of the RIDOC study.
12.3% The decrease in Rhode Island’s overall death rate 
from January 1, 2017 to 
June 30, 2017 compared to 
the previous year.
60.5% The decrease in the overdose death rate 
among those recently 
incarcerated during the 
same timeframe.
50% The overall number of deaths attributed to 
fentanyl was cut in half.
72
35
The number of naloxone 
kits dispensed at release 
from incarceration decreased 
between the 2016 and 2017 
cohorts, while the receipt 
of MAT (buprenorphine, 
methadone, and naltrexone) 
after release increased.
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Kentucky
Summary
In 2015, the Kentucky Department of Corrections (KYDOC) began 
offering extended-release naltrexone (Vivitrol) at eight out of 12 prisons 
and 24 out of 76 jails. A case manager is responsible for coordinating 
all care. In addition to MAT, whole person care is offered both during 
and after incarceration, including cognitive behavioral therapy, general 
aftercare, and relapse prevention support groups.
The average cost of addiction treatment programs is $9.00 per day in all 
KYDOC jails and $6.67 per day in prisons.10 Although the only medication 
offered is extended-release naltrexone (Vivitrol), the program has seen 
significant improvements in healthcare costs, relapse rates, overdoses, and 
recidivism rates.
KYDOC partners with the Department for Local Government and the 
Kentucky Housing Corporation to fund Recovery Kentucky, an addiction 
treatment program that provides housing and continued treatment post-
release. Recovery Kentucky operates 14 addiction treatment housing sites 
across the state, with a particular focus on the reentry population.11
Approximately 70 percent of the beds available for reentry individuals are 
funded by KYDOC on a per diem basis, with up to 180 days provided to 
each participant. Recovery Kentucky maintains Vivitrol treatment, and 
some sites partner with Federally Qualified Health Centers (FQHCs) to 
provide Vivitrol to those not receiving it on entry. The average cost of 
Recovery Kentucky is $35.89 per person per day.12
Setting Prison/jail (on exit); Reentry
Principles ■■ Long-term treatment
■■ Whole person care
Medications ■■ Extended-Release Naltrexone 
Used (Vivitrol)
Program Model
KYDOC’s prisons and jails begin identifying 
individuals with substance use disorders 
six months prior to release. A first injection 
of naltrexone is offered five weeks prior to 
release, and a second injection is delivered 
one week prior to release. Participants continue 
to receive monthly treatment for a minimum 
of six months during reentry.7 After release, 
individuals are referred to post-release services 
directly from corrections custody, including 
Recovery Kentucky. Participants in Recovery 
Kentucky remain in treatment and support 
systems for up to 180 days in accordance with 
best practices that indicate the necessity of 
long-term treatment for success. Upon intake 
into all KYDOC treatment programs, data is 
collected on behaviors prior to incarceration, 
and follow-up data is collected 12 months after 
completion of the program.
Outcomes***
***It should be noted that this program was not limited 
to individuals with opioid use disorder, and therefore the 
outcomes reflect treatment of other substance use disorders.
For every $1 invested in corrections-
based addiction treatment in 
Kentucky, there was a $4.52 return on 
investment, according to a 2018 study 
using data collected from July 1, 2016 
to June 30, 2017.10
70 percent of those who completed 
addiction treatment programming 
were employed 12 months following 
release, 57.2 percent had not been 
reincarcerated, and 61 percent had no 
evidence of illegal drug use.10
In a 6-month follow-up study of Recovery Kentucky:12
$1  $4.52 70% 57% 61%
76%
76 percent employed 
compared to 46 percent 
at intake.
5 percent reported illegal 
drug use compared to 
83 percent at intake.
83% 5% $2.60
return in 
avoided costs.
1$  $6.27
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Massachusetts
Summary
Implemented in 2014, the Medication-Assisted Treatment Reentry 
Initiative (MATRI) is a collaboration between the Massachusetts 
Department of Corrections and the Massachusetts Department of Public 
Health’s Bureau of Substance Abuse Services. MATRI offers pre-
release treatment and post-release follow-up and linkage to treatment for 
individuals identified as having an alcohol or substance use disorders.
For those with opioid use disorders, the program offers Vivitrol 
(naltrexone) on release from Department of Corrections (DOC) custody 
and through 12 months post-release. It also offers a recovery support 
navigator (RSN) to facilitate continued treatment in the community.  
Spectrum Health Services, a medical service provider for incarcerated 
individuals, provides Vivitrol to participants pre-release. On release, 
participants are directly referred to clinics in the community. These 
include 13 intake centers and other clinics maintained by Spectrum 
and at least a dozen other community treatment providers who have 
partnered with DOC.7
MATRI is funded through a combination of Medicaid and 
partnerships. The RSN and aftercare treatment are provided by 
Spectrum. A pharmaceutical company provides Vivitrol to DOC 
for pre-release treatment. Through Medicaid Expansion adopted by 
Massachusetts, post-release Vivitrol is covered by Medicaid, and the 
vast majority of incarcerated individuals are Medicaid eligible.13 
In addition, the Massachusetts DOC received a $1 million allocation 
in 2014 to initiate the program and has received an additional $250,000 
each year since to maintain the program.14
Setting Prison (on exit); Reentry
Principles ■■ Warm hand-off to continued 
service post-release
■■ Community partnerships
Medications ■■ Extended-Release Naltrexone 
Used (Vivitrol)
Program Model
MATRI programming is available at 14 out 
of the 16 Massachusetts state prisons.7 Initial 
screening takes place nine months pre-release. 
Those eligible who are at a facility that does 
not provide programming are transferred to a 
participating facility. After screening, eligible 
inmates attend programming that includes 
MAT education, one-on-one appointments with 
substance use counselors, and therapy groups 
for at least six months.
At six months prior to release, participants 
are paired with RSNs to develop a personal 
recovery plan. To evaluate for possible side 
effects, low doses of oral naltrexone are 
provided daily starting 10 days pre-release. 
Vivitrol is provided seven days prior to release 
and monthly post-release. On release, the RSN 
works directly with participants to coordinate 
and manage treatment for up to one year 
post-release.13
Outcomes
78 percent of those provided 
Vivitrol prior to release 
received some form of 
treatment post-release, 
as of October 2016.15
62 percent of those 
provided Vivitrol prior 
to release received 
MAT post-release.15
78% 62%
$8,986
per inmate
The net benefit of 
treatment after the 
implementation of MATRI 
and other MAT programs 
in Massachusetts 
DOC, according to the 
Massachusetts Results 
First Initiative.16
There was a $6.27 return 
for every dollar invested.16
9.7%
reduction in 
crime as a 
result of the 
programs.16
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Philadelphia, PA†
Summary
The Philadelphia Department of Prisons (PDP) has been providing MAT 
in all city jails for over 12 years. Through a partnership with a community 
treatment provider, PDP has provided methadone maintenance, in 
conjunction with cognitive behavioral therapy (CBT) behind the wall 
in all its jails since the 90s; and in recent years, the program has been 
expanding to address the varying needs of all individuals incarcerated in 
Philadelphia jails, now offering all forms of MAT.17
The program now offers methadone maintenance, Suboxone induction 
and maintenance, and Vivitrol treatment during incarceration; and all 
medication is accompanied by CBT. On release, PDP provides for 
continuity of treatment, Medicaid coverage, and Narcan along with 
Narcan training. PDP expects that of the 25,000 admissions anticipated in 
2019, 25 percent will be individuals with opioid use disorder (OUD), and 
70 percent will require some sort of SUD treatment.
†Unless otherwise indicated, all data and information on 
the Philadelphia program was communicated directly by 
the Philadelphia Department of Prisons.
Setting Jail
Principles ■■ Behavioral treatment available 
in conjunction with MAT
■■ Referral on release
Medications ■■ Buprenorphine/Suboxone
Used ■■ Extended-Release Naltrexone 
(Vivitrol)
■■ Methadone
Program Model
PDP evaluates every individual in its custody on 
day two after entry to determine eligibility for a MAT 
program. All those already induced on Suboxone or 
methadone by a community treatment provider are 
maintained on their medication. Those not already 
on MAT who are identified as suffering from an OUD 
are offered participation in PDP’s Suboxone or 
Vivitrol programs.
PDP began providing buprenorphine in 2017 to 
women not already maintained on methadone.  
About 90 percent of all eligible women opted into 
the program. Since September 2018, this program 
was expanded to all PDP facilities including those 
that house men. About 80 percent of eligible 
men participate. Earlier this year, the program 
converted from buprenorphine alone to Suboxone 
(buprenorphine and naloxone), delivered to 
participants in person-specific blister packs. Vivitrol 
has become available only in recent weeks. All 
providers are trained in its use, and it is now available 
to all entering PDP’s custody. CBT is offered to all 
participants in conjunction with medication.
PDP staff meet with all program participants to 
identify a community “MAT Center of Excellence” 
with whom to continue treatment following release. 
A referral is made to the Center selected by the 
individual for both pre-sentenced and sentenced 
individuals. All individuals in PDP custody are 
released with Medicaid coverage effective no later 
than the date of release. In addition, on release, all 
individuals treated with Suboxone are given at least 
one blister pack of medication to continue post-
release, providing at least five days of medication, 
and all those on medical management of OUD are 
offered a two-dose nasal spray Narcan (naloxone) 
kit on release. All individuals leaving custody receive 
the state’s standing order prescription for Narcan on 
release, and all incarcerated individuals are trained 
regarding overdose risk, the usefulness of Narcan, 
how to administer Narcan, and how to obtain Narcan.
Outcomes
30.6%
Of those who received buprenorphine through the PDP 
program between February and December of 2018, 
30.6 percent engaged in some form of treatment (MAT, 
behavioral, or both) after release. It is important to 
note that from February to August, PDP was offering 
buprenorphine only to women, and they were giving 
prescriptions for at least 5 days of buprenorphine post 
release. Starting in September, the program opened to 
men and stopped offering prescriptions on release. As 
of April 2019, the program transitioned to Suboxone and
reinstituted the use of medication on release, but data 
including this new development is not yet available.
95%
Of those receiving methadone maintenance treatment 
at PDP, 95 percent return to treatment at their home 
clinics post-release.
5.9%
Of the 459 individuals who received treatment during 
2018, 27 were reincarcerated after their first release 
(5.9 percent).
9.1%
4.57%
38.2% 6.83%
COMPLETED CURRENTLY ACTIVE
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Middlesex County, MA‡
Summary
In October 2015, Middlesex Sheriff’s Office (MSO) implemented 
the Medication Assisted Treatment and Direct Opioid Recovery 
(MATADOR) program. The program is voluntary and is offered to all 
individuals entering MSO custody, approximately 1,000 individuals at 
any one time, including pre-trial detainees and sentenced individuals 
serving 30 months or less. The goal of the program is to improve the 
treatment and criminogenic risk factors of those released from MSO by 
utilizing three key strategies: MAT prior to and on release, post-release 
navigation and support, and robust data tracking.18
Central to the success of MATADOR has been continued partnership with 
and referral to community treatment providers able to continue treatment 
post-release.19 As of April 2018, 50 healthcare providers, 75 support 
program locations, and four drug courts throughout Massachusetts were 
willing to accept individuals from MSO and administer continuing 
Vivitrol injections. MATADOR’s program director is a Licensed Practical 
Nurse who also functions as a navigator. A second navigator works 
with the Program Director to guide individuals through treatment and 
communicate with participating community treatment providers. The 
model of navigation has facilitated more effective retention and treatment 
outcomes, as well as improved treatment networks.18
Funding for MATADOR comes from a variety of sources. Much of 
the funding for programming comes directly from the MSO budget, in 
conjunction with two grants, one from federal funding sources and one 
from the state. The initial dose of Vivitrol (naltrexone), administered prior 
to release is funded by the manufacturer, and the following injections are 
mostly or entirely funded by Medicaid.18 Currently, MATADOR offers 
only Vivitrol (naltrexone), but the program is transitioning to providing all 
three forms of MAT (including buprenorphine and methadone).
‡Unless otherwise noted, all outcome data 
and information on the Middlesex program was 
communicated directly by the Middlesex Sheriff’s Office.
Setting Jail (on release); Reentry
Principles ■■ Robust navigation and case 
management
■■ Data collection and utilization
■■ Community linkages
Medications ■■ Extended-Release Naltrexone 
Used (Vivitrol)
Program Model
All individuals entering MSO receive a 
comprehensive medical screening, at which 
time need for SUD treatment is ascertained. 
As of December 2017, 40 percent of all new 
intakes had a severe drug or alcohol addiction 
requiring immediate detox and enrollment; 
of these, 73 percent involved opioids. Once 
assessed, individuals presenting with SUDs 
are placed under medical supervision to 
address any physical symptoms associated with 
addiction, and MSO casework staff educate 
all individuals on available forms of MAT and 
treatment, including the MATADOR program.
Enrollment in the program is voluntary, and over 
70 percent of all participants are self-referred.  
Interested individuals are educated on program 
specifics and are screened again to test for 
medication side effects. MSO staff work with 
participants to obtain all medical clearances to 
ensure seamless transitions and continuity of 
care, and they enroll all participants in Medicaid 
pre-release. An initial injection of Vivitrol is then 
administered 48 hours prior to release.
Prior to release, participants are also 
connected with a navigator to manage care 
post-release.  The navigator follows up with 
released individuals both to act as a resource 
and advocate to address treatment and reentry 
needs, and to serve as a liaison to ensure 
efficient communication with community 
treatment providers. Participants are deemed 
successful after six months of navigation and 
treatment.18
Outcomes
According to a risk assessment tool utilized by MSO, 
all participants have a re-offense risk higher than 
Low; and 88.9 percent are High- to Very High-Risk. 
Nevertheless, MATADOR participants have only a 
14.7 percent reconviction rate and an 8.7 percent 
rate of parole violation.
88.9% 14.7% 8.7%
38.2 percent of participants have completed the 
program, meaning they have received six Vivitrol 
injections and/or six months of negative urine 
tests, compliance with substance use counseling/
treatment, and communication with MSO staff; an 
additional 6.83 percent are currently active and in 
compliance with all requirements.
Of those who fail the 
program (52.5 percent), 
only 9.1 percent do so 
because of a 
reported relapse or 
failed drug test.
To date, only 4.57 percent 
of participants have a 
confirmed fatal overdose after 
participation in the program.
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4
C H A P T E R
Addressing Challenges to
Implementing Evidence-
Based Practices and 
Programs in Criminal 
Justice Settings
Introduction
As reviewed in earlier sections of this guide, dozens of 
studies, including randomized controlled trials, have 
proven that medication-assisted treatment (MAT):
■■ Enhances treatment engagement  
during and after discharge from custody
■■ Decreases relapse rates 
■■ Is associated with reduced criminal recidivism
■■ Is associated with lower overdose deaths and 
health risk behaviors
However, only about one-third to one-half of staff 
members in state correctional institutions, community 
corrections agencies, drug courts, substance use 
treatment programs, and physician practices are aware 
of the health benefits of the medications used in MAT.1-9
The dominant approach to opioid use disorders 
(OUDs) in jails and prisons involves short-term 
detoxification and requires inmates to be tapered off 
proven medications within certain time limits.6,10 When 
buprenorphine or methadone are permitted for medical 
situations requiring immediate action, such as for 
the treatment of pregnant women, discontinuation of 
the regimen is normally required once the qualifying 
condition has ended, such as after childbirth.
With current approaches 
to opioid use disorders in 
jails and prisons...
Relapse rates 
EXCEED 
 75% 
after release  
from custody.11, 12 
Re-arrest rates 
ARE NEARLY 
50%
in the first year.13
Overdose  
death rates are
10  40 
TIMES HIGHER 
for previously incarcerated  
individuals than for the  
general population.14-17
While correctional institutions can face several 
challenges when trying to implement MAT, addressing 
these challenges is key to achieving improved 
outcomes for people currently and previously involved 
with the criminal justice system.
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Challenges to Implementing Medication-Assisted 
Treatment in Criminal Justice Settings 
Challenge  
Overcoming Stigma and Disapproval  
Actions
■■ Avoid stigmatizing language, such as 
“substance abuse,” “addict,” or “relapse”
■■ Educate staff about the disease model of 
addiction and benefits of MAT
■■ Describe disorders that often co-occur with 
or exacerbate substance use disorders
■■ Explain common peer and environmental 
influences on initiation of substance use
■■ Describe low success rates and high 
overdose rates without MAT
Persons suffering from OUD face stigma and 
disapproval of MAT from criminal justice 
professionals and others in their social networks. 
A national survey found that most members of 
the public held negative views towards persons 
with substance use disorders and were skeptical 
about the effectiveness of substance use disorder 
treatment.18
In a 2019 study, more than half (58 percent) of 
drug court participants with OUDs experienced 
or observed negative judgmental reactions 
toward methadone and buprenorphine from 
family members and peers in self-help recovery 
groups.19 A recent report from Narcotics 
Anonymous (NA) World Services confirmed that 
some NA meetings unduly limit participation 
of individuals receiving MAT or may be less 
welcoming of such individuals.20
Negative judgments come in a variety of forms, 
such as minimizing an individual’s recovery 
because he or she is receiving MAT or wrongly 
predicting that use of MAT will eventually 
lead the person back to illicit opioid use. These 
reactions are not merely hurtful, but can interfere 
 
substantially with participants’ confidence in their 
ability to meet treatment goals.21
Several practices have shown promise for 
reducing negative attributions towards persons 
with OUDs and increasing endorsement of 
evidence-based treatments including MAT:22, 23
■■ Using terms associated with 
greater empathy and optimism, such as 
recovery or recurrence of use24
■■ Describing persons’ previously 
unsuccessful efforts to quit using drugs 
without the benefit of proven medications and 
disheartened reactions to those failed efforts
■■ Describing practical misuse 
prevention efforts that can be taken with 
prescription medications, such as observed 
medication ingestion
■■ Referring participants to self-help recovery 
groups that are supportive of MAT or 
preparing them to deal with 
negative reactions they may experience 
in the groups25-28
■■ Educating professionals and 
laypersons about the disease model 
of addiction, including genetic influences, 
neurochemical changes in the brain, and the 
positive effects of MAT
■■ Describing common environmental 
influences on initiation of substance use, 
such as trauma, peer pressures, and poor 
prescription practices
■■ Describing medical and psychiatric 
disorders that often co-occur with and 
exacerbate substance use, such as chronic pain, 
depression, anxiety, and PTSD
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Challenge  
  Addressing  Threats to Safety 
and Security 
Actions
■■ Provide training to staff
■■ Securely store medications
■■ Verify medication ingestion
■■ Conduct pill counts
■■ Use abuse-deterrence formulations
There are several safety and security concerns 
that accompany the implementation of MAT in 
jails and prisons. Diversion and misuse of MAT 
medications are chief among those concerns. 
Nearly two thirds of jails and prisons report 
instances of nonprescribed use of buprenorphine, 
and approximately 20 percent report “cheeking” 
or other unauthorized concealment of prescribed 
buprenorphine.29, 30
To address these concerns, correctional medical 
staff must be educated and trained on how to 
properly and securely store and administer 
medications.31 MAT medications should be 
stored in secured areas with locked cabinets and 
refrigerators.31 The actual setting of medication 
administration may differ depending on the size 
of the facility, individuals’ custody levels and 
housing locations.32 Institutions must determine 
which procedures work best.
Common procedures for medication 
administration in correctional settings include:32, 33
■■ Scheduled pill call lines within 
housing units
■■ Dispersal windows (required by the 
DEA for dispensing methadone)
■■ Administration of medications in a 
centralized location such as a 
medical clinic or infirmary
 
■■ Individual inmate release from their 
cells to a nearby nurse’s medication cart
■■ Cell to cell administration of 
medications for high risk inmates
■■ Specialized units for persons receiving 
MAT or substance use treatment
Arrangements such as pill call lines or dispersal 
windows can call attention to individuals 
receiving MAT and contribute to stigma or 
pressure from others to divert the medication for 
unauthorized purposes. Individual administration 
or special units help to avoid these problems but 
require more staff time and resources. 
When administering medications, staff should 
closely supervise individuals to decrease the 
possibility of diversion or misuse.34 Dispensing 
medication in the form of a soluble film or liquid 
makes it considerably more difficult to avoid 
ingestion. Requiring persons to consume juice, 
crackers, or water after ingestion helps to avoid 
“cheeking,” and inspecting under the person’s 
tongue and around the gums are methods for 
ensuring full ingestion.32 Dual mouth-checks 
by both medical and correctional staff reduce 
inadvertent lapses of attention that can cause 
staff to miss non-ingested medications.35 
Random pill counts and urine screening to 
ensure medication is being taken are also 
methods used to monitor diversion.
All jail and prison staff, not just those dispensing 
medications, should receive in-service 
trainings on MAT, including an overview of 
the institution’s MAT policies and procedures, 
basic information about what MAT is and its 
benefits, potential side-effects of the medications 
warranting clinical attention, and signs of 
medication diversion.35
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For individuals who refuse or miss a dose, staff 
must fill out documentation accounting for the 
missed dose and return it to secure storage.32, 33 If 
possible, staff should get the individual’s signature 
confirming the medication was not taken. Staff must 
ensure medications are used before expiration. Both 
injectable buprenorphine and naltrexone require 
refrigeration and, once allowed to warm to room 
temperature, must be used within 7 days.31
For institutions interested in or already using 
buprenorphine or naltrexone, there are abuse- 
deterrence formulations of these medications.34, 36 
Suboxone, a combination of buprenorphine with 
naloxone that is taken sublingually, causes symptoms 
of withdrawal when injected. Vivitrol, a long-lasting 
formulation of naltrexone, or Sublocade, an extended-
release injection of buprenorphine, eliminates the 
need for daily dosing.
Employing a combination of these methods 
and procedures can help address safety and 
security concerns.
Challenge  
Advancing Staf f Knowledge and Skills
Actions
■■ Provide ongoing staff training
■■ Develop working groups comprised of 
corrections staff and community providers
■■ Institute ongoing peer supervision
■■ Establish peer mentoring
■■ Appoint change agents
Training correctional staff on the proven 
benefits of MAT and addressing prevalent 
misconceptions about the medications is a 
necessary first step in changing attitudes and 
practices. In-person and online training curricula 
have been demonstrated to enhance knowledge 
of, attitudes towards, and willingness to adopt 
MAT among criminal justice and non-criminal 
justice professionals.2, 37-40
However, online training alone is not enough to 
sustain this change because the effects have been 
found to degrade within one month and increases 
in knowledge do not necessarily translate into 
actual referrals to MAT.37
To encourage adoption and long-term support 
for MAT, training and other staff engagement 
initiatives must provide ongoing opportunities 
for staff to build skills, recall information, 
share knowledge, and deepen understanding. 
A randomized controlled trial conducted in 
20 community corrections agencies found 
that combining training on MAT with an 
organizational linkage intervention significantly 
enhanced staff referrals to MAT.6 
The three-hour training taught correctional staff 
about the neurobiological basis of OUDs, the 
effects of agonist and antagonist medications 
in treating the illness, compatibility of MAT 
with behavioral counseling, and available MAT 
resources in the local community. In addition, 
representatives from the corrections agencies 
and local MAT providers met regularly for 12 
months to discuss mutual concerns and resolve 
barriers to MAT service referrals and provision. 
Although training alone was adequate to 
enhance knowledge of and attitudes towards 
MAT, only the combined intervention 
significantly improved current and future 
MAT referral intentions.6
A study conducted in 54 state correctional 
facilities found that training staff on the 
benefits of naloxone for reducing overdose 
mortality improved knowledge and attitudes 
about overdose reversal; however, knowledge 
acquisition did not necessarily translate 
into changes in practice.7 Equipping staff 
with naloxone reversal kits, teaching them 
to assemble the applicators, and providing 
videotaped booster trainings improved staff 
members’ confidence in their ability to intervene 
successfully in an overdose emergency and led 
to increased uptake of naloxone reversal kits by 
correctional officers and inmates.7
  
Use of Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings
Addressing Challenges to Implementing Evidence-Based Practices and Programs in Criminal Justice Settings
52
Additionally, other studies have reported increased 
adoption of evidence-based practices including 
MAT in community corrections agencies and drug 
courts when programs offered peer supervision 
or mentoring to help staff maintain and update 
knowledge and skills and appointed change agents 
(“champions”) within the program to advocate for 
continued managerial and administrative support 
for the services.41, 42
$
   
Challenge  
Covering the Cost of MAT 
Actions
■■ Seek discounted MAT rates through state block 
grants or appropriations, Federally Qualified 
Health Centers (FQHCs), and subsidized 
medication programs
■■ States temporarily suspend or reclassify 
Medicaid coverage during incarceration rather 
than terminate Medicaid eligibility
■■ Employ benefits assistants to screen incarcerated 
persons for coverage eligibility, help them enroll, 
and encourage engagement in covered services
■■ Develop automated data exchanges to alert 
Medicaid and community providers about 
upcoming discharges of eligible or enrolled 
participants and share relevant information
■■ Have case management staff meet with 
incarcerated persons while in custody to 
coordinate post-release healthcare and social 
services
■■ Use peer support specialists with relevant 
lived experience to support reentry and 
engagement in treatment post-release 
■■ Address social determinants of health that 
can interfere with MAT outcomes via health 
homes and other supportive social services
■■ Allow community treatment providers to 
bill public or private insurers for in-reach 
services delivered in preparation for 
discharge from custody
 
Many states fund MAT for programs serving 
correctional populations out of state block grants 
or direct appropriations. In addition, more than 
1,200 FQHCs located in inner-city and rural 
areas offer buprenorphine at discounted fees 
for uninsured and low-income individuals.31 
Some jails, prisons, and community corrections 
agencies have also been able to negotiate reduced- 
price medications directly from pharmaceutical 
companies.
The 340B Drug Discount Program is a federal 
government program requiring drug manufacturers 
participating in Medicaid to provide outpatient 
medications to eligible health care organizations 
and other covered entities at significantly reduced 
prices. Covered entities serve highly vulnerable 
populations, including hospitals treating a 
disproportionate share of poor and uninsured 
patients, sole community hospitals, and rural 
referral centers, many of which treat justice-
involved individuals. Covered entities may be 
required to provide discounted medications to 
uninsured patients and those covered by Medicare, 
Medicaid or private insurance.
By far, the most common reimbursement for MAT 
comes from Medicaid, covering nearly 40 percent 
of all nonelderly persons with OUDs in 2017.43 
With a few limited exceptions, persons in jails 
or prisons are not eligible for Medicaid or most 
types of insurance while incarcerated. However, 
legislative changes implemented in the Affordable 
Care Act have greatly expanded coverage for MAT 
and related services during community reentry.
As of midyear 2018, people with incomes 
below 138 percent of the federal poverty level 
are Medicaid-eligible in at least 33 states and the District 
of Columbia, and many are eligible for insurance subsidies 
in non-expansion states as well. Medicaid coverage 
is available for persons on probation or parole, under 
home confinement, and in community-based correctional 
residential programs (e.g., halfway houses) so long as 
they are free to leave the facility during work or other 
specified hours.44
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All state Medicaid programs cover at least one 
medication used to treat OUDs and many states 
cover all three FDA-approved medications. 
As of February 2018, 36 states and territories 
covered methadone, 51 covered buprenorphine, 
49 covered naltrexone, and more than half 
increased coverage for naloxone to reverse 
opioid overdose.45, 46
States also have discretion under Medicaid to 
cover “rehabilitative” services broadly defined 
to include peer support specialists, supportive 
housing and supported employment services 
such as job coaching. As of April 2019, 28 
states sought or received Medicaid waivers to 
provide substance use treatment to include MAT, 
counseling and community support services.43
Health homes have been established to address 
the complex service needs presented by persons 
with serious mental health disorders or two or 
more other chronic health conditions including 
substance use disorders. Innovative models of 
healthcare delivery can help tailor treatment to 
the needs of formerly incarcerated individuals. 
For example, at least 11 states and Puerto Rico 
have established interdisciplinary care support 
teams (“Transitions Clinic Networks”) to 
coordinate post-release healthcare and social 
services for justice-involved persons.
Barriers nevertheless persist in gaining 
meaningful access to Medicaid and other 
reimbursement coverage. Managed care entities 
may impose burdensome prior authorization 
conditions, require certain medications to 
be used as the front-line regimen, or place 
restrictions on the dose, quantity or duration 
of MAT.47, 48
Some states have been approved to impose 
work requirements on Medicaid coverage, 
cancel coverage for timely failure to renew 
plans or report changes affecting eligibility, 
charge premiums of up to 5 percent of family 
income, place restrictions on non-emergency 
transportation for treatment, and impose fees 
for missed appointments.49, 50
Navigating these complex coverage requirements 
can be prohibitively difficult for persons in the 
criminal justice system. Fortunately, several 
strategies have proven successful in creating 
better linkages to healthcare coverage for MAT 
and enhancing access to needed services.44, 51 
Suspending or reclassifying Medicaid coverage, 
rather than terminating coverage, reduces 
unnecessary burdens on reinstatement. States 
also have discretion under Medicaid to cover 
benefits assistants to help identify and enroll 
eligible persons in Medicaid while they are 
incarcerated and case management services to 
help beneficiaries identify, apply for, and enroll 
in treatment and social support programs after 
release to the community.
States may cover peer support specialists 
with lived experience related to substance 
use disorders and justice system involvement 
to help individuals navigate the health care 
system and make it to scheduled appointments. 
Finally, some states are experimenting with 
ways for community treatment agencies to bill 
for in-reach therapeutic services delivered in 
preparation for discharge from custody.48
The Affordable Care Act also provides the 
following funding for data exchanges to 
improve information sharing and coordination 
of efforts between Medicaid, prisons or jails, 
and community treatment providers:
■■ Up to 90 percent cost-matching to 
help states build and promote the exchanges
■■ 75 percent cost-matching for 
ongoing maintenance and operation 
of the exchanges
■■ Incentive payments for health 
providers to use electronic records
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Challenge  
Establishing Institutional MA T Providers
Actions
■■ Obtain required institutional licensing
■■ Obtain required staff certification
■■ Partner with community-based providers
■■ Garner the individual’s buy-in for 
transitioning medications where indicated
Not all jails or prisons have ready access to MAT 
providers. Methadone can only be administered 
by a state and DEA-licensed opioid treatment 
program (OTP), and buprenorphine may only be 
administered by trained and waivered medical 
practitioners. If a jail or prison has not obtained 
licensing or does not have staff with the proper 
credentials, it will be required to partner with a 
community-based OTP or medical providers.
Several online directories included in the next 
chapter of this guide provide information on 
physicians and treatment agencies specializing 
in addiction medicine or addiction psychiatry. 
Most of these websites can be queried by 
city, state, or zip code to identify medical 
practitioners in a nearby community. In addition, 
single-state agencies for substance use disorder 
treatment usually maintain lists of credentialed 
providers, including those authorized to provide 
office-based treatment with buprenorphine. 
Colleges, universities, and medical schools are 
also excellent resources for locating substance 
use disorder specialists. Finally, state or 
county boards of health can identify medical 
practitioners offering substance use disorder 
treatment in their area.
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Methadone Providers
Qualified medical or nursing staff from 
community OTPs may go to the correctional 
facility to dispense methadone daily under the 
supervision or observation of jail or prison 
authorities.31 Methadone may also be dispensed 
by jail or prison pharmacy staff for up to 
three days for purposes of ensuring treatment 
continuity. This permits methadone to be 
provided, for example, when a community 
OTP is closed on weekends or an individual is 
serving a brief weekend jail sanction.
Buprenorphine Providers
Buprenorphine may be prescribed outside 
of a licensed OTP by a physician who has 
completed an 8-hour training and obtained 
a waiver pursuant to the Drug Addiction 
Treatment Act of 2000 (DATA-2000) or by a  
nurse practitioner or physician assistant who 
has completed 24 hours of approved training 
and who have obtained a waiver. Having jail 
or prison medical staff obtain buprenorphine 
waivers is far simpler and less costly than 
becoming licensed as an OTP.
For institutions that are unable to partner 
with community OTPs, evidence suggests 
inmates can be transitioned successfully 
from methadone to buprenorphine under the 
supervision of trained medical personnel.10, 31 
Substantial familiarity with this procedure is 
required to ensure it is accomplished safely 
and effectively. Medical practice guidelines 
require strict procedures for tapering 
the methadone dose before introducing 
buprenorphine at specified increments to 
avoid inducing withdrawal.
If methadone is reasonably available, however, 
substituting buprenorphine should be based 
on medical judgment and not required as a 
matter of policy. The effectiveness of MAT is 
reduced significantly when programs override 
an individual’s wishes and change a medication 
regimen that has been effective.52
Naltrexone Providers
Naltrexone, including the extended-release 
formulation, does not require a special license 
to prescribe and can be readily available in 
most jails and prisons. For this reason, some 
institutions may require inmates to transition 
from methadone or buprenorphine to naltrexone. 
Such policies are not recommended.
Transitioning from methadone or buprenorphine 
to naltrexone requires clinical training and 
expertise. Individuals must be fully and 
comfortably medically withdrawn from 
all opioid medications prior to introducing 
naltrexone to avoid causing a severe and 
potentially hazardous withdrawal. And, as 
already noted, changing regimens without the 
person’s buy-in undermines the effectiveness 
of MAT.
Use of Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings
Addressing Challenges to Implementing Evidence-Based Practices and Programs in Criminal Justice Settings
56
   
Challenge  
Building Partnerships to Facilitate 
Linkage to Community-Based Treatment 
Actions
■■ Partner with existing community providers
■■ Ensure partner providers are comfortable 
and skilled in working with justice-involved 
persons  
■■ Build a network of existing resources and 
services for justice-involved persons
Many jails and prisons need to collaborate with 
community providers to deliver MAT and other 
services in the institution and after release. 
The factor that best distinguishes effective from 
ineffective prison and jail-based MAT programs 
is whether participants experienced a smooth 
transition to follow-up care after release to 
the community.53, 54
Significant reductions in opioid overdose and 
mortality have only been observed when MAT 
was initiated in custody and continued for at 
least 4 consecutive weeks after release.55, 56 
Significant improvements in criminal recidivism 
and employment are typically achieved when 
post-release supervision and counseling are 
delivered for at least 8 hours per week over 
6 months.57, 58
Providing post-release MAT is complicated 
by the fact that over 80 percent of OTPs in the 
United States are at or above capacity, most are 
situated in urban or high-population density 
areas, and strict requirements for provision of 
psychosocial services often lead to long wait lists 
for treatment.47, 59
 
Office-based treatment with buprenorphine is 
intended to reach larger numbers of persons in 
need. After completing an eight-hour training 
and receiving a DATA-2000 waiver, specialist 
physicians (e.g., those board-certified in addiction 
medicine or psychiatry) may treat up to 100 
individuals in the first year and 275 individuals 
thereafter. Waivered physician assistants and 
nurse practitioners can treat up to 100 individuals. 
Still, few eligible practitioners (less than five 
percent) are waivered to prescribe buprenorphine 
in rural communities, where the opioid epidemic 
tends to be most severe.47 Sustained outreach is 
needed to enlist more providers to obtain DATA- 
2000 waivers and serve populations in need. 
Naltrexone does not require special training or 
certification to administer; therefore, enlisting 
naltrexone providers should be relatively easier to 
accomplish.
Criminal justice professionals are advised to 
reach out to state and local medical societies, 
hospitals, community health centers and physician 
practices to educate medical professionals in their 
community about the need for their services and 
develop collaborative working relationships. 
Enlisting providers is the first step; however, 
ongoing collaboration and interdisciplinary 
training is essential to ensure they are comfortable 
working with criminal justice populations, remain 
abreast of best practices relating to MAT, and 
share information effectively with criminal justice 
professionals. Several states, including Vermont 
and Rhode Island, developed “hub-and-spoke” 
models to serve criminal justice and non-criminal 
justice populations.10 The hubs are specialized 
treatment centers with expertise in MAT and 
other substance use treatment services located 
strategically in different geographic regions of 
the state. The spokes are interdisciplinary teams 
comprised of a care coordinator, counselor, and 
physician, situated within local communities.
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The spoke teams maintain active data-exchanges 
with the hubs concerning patient care and 
participate in learning collaboratives on topics 
related to MAT and treatment of justice- 
involved persons. Initial treatment planning 
and stabilization typically occur at a hub, and 
participants may then be transferred to a local 
spoke team for continuing care and medication 
maintenance. In the event of relapse or health- 
related emergency, individuals are ordinarily 
referred back to the hub program instead of being 
re- incarcerated or discharged from treatment.
This model links existing programs into learning 
and practice collaboratives and does not require 
a  major influx of new resources. Practice settings 
for the hubs are typically university-affiliated 
medical centers or tertiary care hospitals, and 
spokes include primary care centers, federally 
qualified health centers, and solo practices.
Early results from the hub and spoke models 
are promising. Reported benefits include:60, 61
■■ Significant reductions in wait lists, 
appointment delays, and 
overdose deaths among formerly 
incarcerated individuals
■■ Larger numbers of physicians obtaining 
DATA-2000 buprenorphine waivers
■■ Timely bi-directional transfer of 
patient information and referrals between 
the hub and spoke programs and criminal 
justice agencies
Spoke teams should include community 
corrections officers working collaboratively with 
treatment professionals to coordinate services. 
Outcomes in reentry are significantly better when 
supervision officers carefully monitor participant 
progress, use motivational enhancement 
techniques to increase compliance with treatment, 
reward achievement of treatment goals, and 
administer gradually escalating consequences, 
short of reincarceration, for treatment attrition or 
other infractions.57, 58, 62, 63
   
Challenge  
Addressing Psychosocial Needs 
of Transitioning Individuals
Actions
■■ Enroll transitioning individuals in 
wraparound services
■■ Begin transition planning prior to release 
to ensure continuation of MAT 
■■ Help transitioning individuals identify barriers 
to and resources for community reintegration
■■ Refer transitioning individuals to community 
providers and support groups
There are several challenges associated 
with transitioning back into the community 
and continuing MAT, including lack of 
transportation, housing instability, need of 
employment, and lack of social support.11
Individuals transitioning from jail or prison 
to community settings are challenged to 
assume greater personal responsibility for their 
treatment and recovery. These individuals are 
transitioning from making treatment decisions 
in controlled settings to making those decisions 
in the context of less controlled conditions. For 
example, exposure to drug use in transitional 
housing arrangements can contribute to relapse, 
or stressful social situations, such as strained 
relationships with family, can contribute to 
feelings of hopelessness and isolation.11 To help 
this transition, offer enrollment in wraparound 
services. Provide referrals to treatment providers 
and assistance with transportation to those 
providers prior to release. Identify local support 
groups as a resource for positive social support 
for individuals returning to the community. 
Helping incarcerated individuals identify and 
anticipate barriers to community reintegration, as 
well as the resources to address them, supports 
successful reentry.62
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Challenge  
Engaging Individuals in MA T Services
Actions
■■ Identify MAT-eligible individuals
■■ Educate eligible individuals about 
medications and overdose risk 
■■ Educate eligible individuals about naloxone
Screening is an essential first step for identifying 
individuals who are eligible for MAT services 
and for establishing a clear baseline for 
treatment services. 
For many reasons, not all eligible individuals 
will be motivated to engage in MAT. Engaging 
individuals to help them understand all aspects 
of the treatment and to dispel myths and 
misinformation is key. MAT education must 
include information on the medications used, 
the risk of overdose, and the use of naloxone 
for overdose prevention.22, 23
Motivational interviewing techniques can 
be used to improve MAT engagement, help 
individuals become more hopeful about their 
recovery, and strengthen their ability to change 
drug-using behaviors and make needed 
life changes.64, 65
 
 
Conclusion
Correctional institutions face attitudinal, financial, and 
resource challenges to implementing MAT, but these 
challenges can be overcome to change the standard 
of care in correctional institutions. Different policies, 
procedures, and practice models exist that improve the 
feasibility of implementing MAT for OUDs in criminal 
justice settings.
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Developing a program for medication-assisted 
treatment (MAT) in a criminal justice setting that is 
based on promising and evidence-based practices, 
guidelines, principles, and procedures is key to setting 
a foundation for successful implementation. This 
chapter calls attention to evidence-based resources 
that are available to support greater access to and 
effective use of MAT in jails, prisons, and other 
criminal justice programs. 
Assessment, Screening, 
and Diagnosis of Opioid 
and other Substance 
Use Disorders
Some jails and prisons may wait until individuals 
exhibit apparent physiological signs of withdrawal 
before evaluating them for MAT or medically 
supported withdrawal (detoxification). Such practices 
should not be used, given the potential harm. 
Experiencing opioid withdrawal (“cold turkey”) is not 
therapeutic, and treating withdrawal from the outset 
is the standard of care.1-4 The medications in MAT, 
like most medical treatments, are most effective when 
administered before symptoms worsen and persons 
are in acute distress. 
5
C H A P T E R
Resources to Support 
Effective Use of 
Medication-Assisted 
Treatment in Criminal 
Justice Settings
Persons entering jail or prison should be screened 
routinely at intake for symptoms of substance use 
and mental health disorders, prior substance use 
and mental health treatment history, prescribed 
medications, withdrawal symptoms, cravings, and 
overdose history. Individuals who screen positive as 
having a potential opioid use disorder (OUD) should 
be examined as soon as possible by medical personnel 
trained to conduct a full diagnostic evaluation and 
assess the person’s suitability for and interest in 
MAT. Below are examples of validated screening and 
assessment tools commonly used for these purposes:
Withdrawal
■■ Clinical Institute Narcotic Assessment (CINA) 
Scale for Withdrawal Symptoms
■■ Clinical Institute Withdrawal Assessment for 
Alcohol–Revised (CIWA-Ar)
■■ Clinical Opiate Withdrawal Scale (COWS)
■■ Subjective Opiate Withdrawal Scale (SOWS)
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Cravings
■■ Brief Substance Craving Scale (BSCS)
■■ Heroin Craving Questionnaire (HCQ)
■■ Opioid Craving Scale (OCS)
Overdose Risk
■■ Assessing Risk for Overdose: Key 
Questions for Intake Forms
■■ Current Opioid Misuse Measure (COMM)
■■ Risk Index for Overdose or Serious Opioid-Induced 
Respiratory Depression (RIOSORD)
Assessment of Opioid and Other 
Substance Use Disorders
■■ Addiction Severity Index (ASI)
■■ Drug Abuse Screening Test (DAST)
■■ Global Appraisal of Individual Needs (GAIN)
■■ Rapid Opioid Dependence Screen (RODS)
■■ Severity of Opioid Dependence 
Questionnaire (SODQ)
■■ Structured Clinical Interview for the 
DSM-5 (SCID-5)
■■ Texas Christian University (TCU) Drug 
Screen-5-Opioid Supplement
Co-Occurring Mental Health Disorders
■■ Brief Jail Mental Health Screen (BJMHS)
■■ CJ-DATS Co-Occurring Disorder Screening 
Instrument (CJ-CODSI)
■■ Global Appraisal of Individual Needs (GAIN)
■■ Mental Health Screening Form-III (MHSFIII)
■■ Modified Mini-Screen (MMS)
■■ Symptom Checklist-90-Revised (SCL-90-R)
■■ U.S. Department of Justice Mental Health Screens 
for Corrections
Trauma History and PTSD
■■ Adverse Childhood Experiences (ACE) 
International Questionnaire
■■ Life Events Checklist for DSM-5
■■ Post-Traumatic Stress Disorder (PTSD) 
Checklist (PCL)
■■ Trauma History Screen (THS)
■■ Trauma Screening Questionnaire (TSQ)
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Medically Supported 
Withdrawal 
(Detoxification)
Some jails, prisons, and drug courts require 
individuals to withdraw from or taper off all opioids, 
including opioid medications such as methadone and 
buprenorphine, within a specified time, typically a 
few days or weeks.5 Forced withdrawal from opioids, 
including prescribed opioid medications, can be 
medically hazardous, reduces the likelihood that 
individuals will participate in substance use disorder 
treatment or MAT in the future,6, 7 and poses a serious 
risk of overdose or death after release from custody 
if the individual returns to pre-incarceration levels 
of opioid use.5
As described in Chapter 1, medically supported 
withdrawal is a complicated procedure designed to 
reduce the acute physiological effects of opioids while 
minimizing withdrawal discomfort, cravings, and other 
debilitating symptoms. Relapse rates are extremely 
high after detoxification alone;2-5 therefore, medically 
supported withdrawal should always be followed by 
a formal course of substance use disorder treatment. 
Practice guidelines are available to help medical staff 
in correctional facilities perform medically supported 
withdrawal safely, effectively, and humanely. As 
noted, such practices should not be conducted as a 
routine course, but rather when medically indicated 
and in consultation with the individual.
■■ Detoxification and Substance 
Abuse Treatment (Treatment 
Improvement Protocol No. 45) 
This Substance Abuse and Mental Health Services 
Administration (SAMHSA) Treatment Improvement 
Protocol (TIP) provides clinical evidence-based 
guidelines, tools, and resources to assist medical 
practitioners to perform safe and effective medically 
supported withdrawal. 
https://store.samhsa.gov/system/files/sma15- 
4131.pdf
■■ Detoxification of Chemically 
Dependent Inmates 
This clinical guidance from the Federal Bureau of 
Prisons provides recommended standards for the 
medical management of withdrawal from addictive 
substances for chemically dependent federal inmates. 
https://www.bop.gov/resources/pdfs/detoxification.
pdf
Medication Choice, 
Dosage, and Duration
Deciding which medication to prescribe, the most 
appropriate dosing regimen, and the indicated duration 
of treatment requires considerable medical training 
and expertise.1-4 
Expert guidance and practice guidelines are available 
to help medical practitioners working in correctional 
settings administer the most appropriate, safe, and 
effective MAT regimen, consulting and advising 
individuals about the benefits and risks of different 
medications:
■■ Decisions in Recovery: Treatment for 
Opioid Use Disorder  
This handbook, developed by SAMHSA, is designed 
for anyone seeking information about or help with 
recovery from OUD. It describes the risks and benefits 
of the different medications.  
https://store.samhsa.gov/system/files/sma16- 
4993.pdf
■■ Medications for Opioid Use Disorder 
for Healthcare and Addiction 
Professionals, Policy Makers, Patients 
and Families (Treatment Improvement 
Protocol No. 63) 
This SAMHSA TIP reviews best practices for 
prescribing the three FDA-approved  medications 
for OUD treatment— methadone, naltrexone, and 
buprenorphine—and other strategies and services 
needed to support people in recovery.  
https://store.samhsa.gov/system/files/sma18-
5063fulldoc_0.pdf
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■■ National Practice Guideline for the 
Use of Medications in the Treatment 
of Addiction Involving Opioid Use 
This national practice guideline, developed by the 
American Society of Addiction Medicine (ASAM), 
provides information on evidence-based MAT of OUD 
and management of opioid overdose. 
https://www.asam.org/docs/default-source/
practice-support/guidelines-and-consensus-docs/
asam-national-practice-guideline-supplement.
pdf?sfvrsn=24
Jail, Prison, and Drug 
Court Programming
Several resources are available to help jail, prison, 
and drug court staff integrate MAT into daily 
operations and offer practical guidance for reducing 
misuse and diversion of medications.
■■ Jail-Based Medication-Assisted 
Treatment: Promising Practices, 
Guidelines, and Resources for the Field   
The National Commission on Correctional Healthcare 
and the National Sheriffs’ Association created this 
resource to provide best and promising practices; 
existing standards and guidelines; and case studies 
with lessons learned, resources, and documentation for 
developing, implementing, and sustaining a jail-based 
MAT program.  
https://www.ncchc.org/filebin/Resources/Jail-Based-
MAT-PPG-web.pdf
■■ Medication Assisted Treatment: 
Effective Application in Jails and 
Prisons Webinar (2016)   
This webinar from the American Correctional 
Association (ACA) discusses the need for MAT 
programs in the correctional field, provides examples 
of MAT programs operating in correctional settings, 
and describes the evaluation and outcomes of MAT 
programs. 
http://www.aca.org/ACA_Prod_IMIS/ACA_Member/
Healthcare_Professional_Interest_Section/
Medication_Assisted_Treatment.aspx
■■ Medication-Assisted Treatment 
for Opioid Use Disorder in the 
Justice System  
This fact sheet was developed by the American 
Association for the Treatment of Opioid Dependence 
(AATOD) to provide an overview of the MAT 
medications and the legal and policy considerations for 
using MAT for OUD in the justice system.  
http://www.aatod.org/wp-content/uploads/2017/10/
AATOD-MAT-Fact-Sheet-wl.pdf
■■ Medication-Assisted Treatment in 
Drug Courts: Recommended Strategies 
This report from the Legal Action Center is designed 
to assist drug court practitioners in understanding MAT 
for OUD and incorporating MAT into their practice. 
https://lac.org/wp-content/uploads/2016/04/
MATinDrugCourts.pdf
■■ Prison/Jail Medication Assisted 
Treatment Manual  
This manual from the Bureau of Justice Assistance 
is designed to assist administrators of correctional 
institutions with establishing quality MAT programs for 
individuals struggling with substance use disorders in 
custody and after release. 
http://www.rsat-tta.com/Files/RSAT_Prison_Med_
Treat_FINAL.pdf
■■ Joint Public Correctional Policy on the 
Treatment of Opioid Use Disorders for 
Justice Involved Individuals 
This policy statement from the ACA and ASAM 
developed recommendations for correctional systems 
and programs to provide evidence-based care to 
individuals with opioid use disorders. 
https://www.asam.org/docs/default-source/public-
policy-statements/2018-joint-public-correctional-
policy-on-the-treatment-of-opioid-use-disorders-for-
justice-involved-individuals.pdf?sfvrsn=26de41c2_2
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Overdose Reversal
Tolerance for opioids declines substantially if inmates 
are not treated with buprenorphine or methadone, 
making them vulnerable to overdose and death after 
release if they return to pre-incarceration levels of 
opioid use.8 Providing inmates with overdose reversal 
medications such as naloxone (Narcan) upon release 
is associated with reduced rates of opioid overdose.9 
Toolkits and instructional guides are available to 
equip inmates with naloxone and provide education to 
reduce overdose risk.
■■ How to Use Naloxone to Reverse 
Opioid Overdose and Save Lives  
This Partnership for Drug-Free Kids webpage provides 
information on the signs of overdose, what to do if 
there is an overdose, and how to administer naloxone.  
https://drugfree.org/article/overdose-response-
treatment/
■■ Opioid Overdose Prevention Toolkit 
This SAMHSA toolkit equips providers, communities, 
and local governments with strategies for developing 
practices and policies to prevent opioid-related death 
and overdose.   
https://store.samhsa.gov/product/Opioid-Overdose-
Prevention-Toolkit/SMA18-4742
■■ Opioid Overdose Reversal with 
Naloxone (Narcan, Evzio) 
This National Institute on Drug Abuse webpage 
provides information on how to obtain and administer 
naloxone to reverse opioid overdose.   
https://www.drugabuse.gov/related-topics/opioid-
overdose-reversal-naloxone-narcan-evzio
Community Providers
Identifying competent and appropriately credentialed 
community MAT providers is critical for ensuring 
continuation of services after release from custody. 
The following websites provide directories of 
physicians or treatment agencies specializing in 
addiction medicine or addiction psychiatry. Most of 
these websites can be queried by city, state, or zip 
code to identify medical practitioners located in a 
released individual’s home community.
■■ American Academy of 
Addiction Psychiatry (AAAP) 
This is a listing of AAAP membership, 
organized by state. 
https://www.aaap.org/patients/find-a-specialist/
■■ American Board of Addiction 
Medicine (ABAM) 
This is a listing of physicians who hold an active 
ABAM certification. 
www.abam.net/find-a-doctor
■■ American Society of Addiction 
Medicine (ASAM) 
This is a searchable listing of ASAM membership. 
https://asam.ps.membersuite.com/directory/
SearchDirectory_Criteria.aspx
■■ SAMHSA Behavioral Health 
Treatment Services Locator  
This locator describes services available in behavioral 
health treatment facilities that have responded to 
SAMHSA’s National Survey of Substance Abuse 
Treatment Services (N-SSATS) and National Mental 
Health Services Survey (N-MHSS).  
https://findtreatment.samhsa.gov/
■■ SAMHSA Buprenorphine 
Practitioner Locator 
This locator includes practitioners authorized to treat 
opioid dependence with buprenorphine by state  
https://www.samhsa.gov/medication-assisted-
treatment/practitioner-program-data/treatment-
practitioner-locator
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■■ SAMHSA Opioid Treatment 
Program Directory 
This directory includes licensed opioid treatment 
programs by state. 
https://dpt2.samhsa.gov/treatment/directory.aspx
Buprenorphine Waivers
Only about five percent of eligible medical providers 
have received DATA-2000 waivers to provide 
buprenorphine treatment for OUDs.2, 3 Resources are 
available to help medical practitioners complete the 
requisite training and obtain buprenorphine waivers. 
■■ American Association of Nurse 
Practitioners (AANP)  
This site offers 16- and 24-hour training courses for 
nurse practitioners and physician assistants. 
https://aanp.inreachce.com/searchresults?sea
rchtype=1&category=e5f98b0f-eafe-4f64-9779-
383732cd8a10
■■ ASAM eLearning   
This site offers training curricula and information 
on certification procedures for physicians to obtain 
buprenorphine waivers. 
https://elearning.asam.org/buprenorphine-waiver-
course
■■ Providers Clinical Support 
System (PCSS)  
This site offers MAT training courses for physicians, 
nurse practitioners and physician assistants to obtain 
buprenorphine waivers.  
https://pcssnow.org/medication-assisted-treatment/
■■ SAMHSA Buprenorphine 
Waiver Management 
This site offers information and assistance on the 
process for obtaining and maintaining 
buprenorphine waivers. 
https://www.samhsa.gov/medication-assisted-
treatment/training-materials-resources/
buprenorphine-waiver
■■ SAMHSA Buprenorphine Training 
for Physicians 
This site offers information on training curricula for 
buprenorphine waivers. 
https://www.samhsa.gov/medication-assisted-
treatment/training-materials-resources/
buprenorphine-physician-training
Peer Support Groups
Many peer recovery support groups may have 
negative attitudes towards MAT or agonist 
medications. Resources are available to help identify 
peer support groups open to individuals using MAT.
■■ Medication-Assisted Recovery 
Anonymous (MARA)  
This website offers information on self-help groups 
that are welcoming of individuals using MAT and 
offers a locator service to find such groups in local 
communities.  
http://mara-international.org/
Additional Resources
■■ American Association for the Treatment 
of Opioid Dependence (AATOD)  
The AATOD website has several resources for the use 
of MAT for OUDs in criminal justice settings. 
http://www.aatod.org/
■■ American Correctional 
Association (ACA)  
The ACA website includes several resources on 
correctional health care, including webinars and 
trainings on MAT in jails and prisons. 
http://www.aca.org/ACA_Prod_IMIS/ACA_Member/
Home/ACA_Member/Home.aspx
■■ Bureau of Justice Assistance (BJA) 
Comprehensive Opioid Resource Center  
The BJA online resource center contains educational 
materials on opioid programs for justice-involved 
persons, descriptions of promising and evidence-based 
programs, profiles of BJA grantees and funding, and 
training and technical assistance opportunities. 
https://www.coapresources.org/
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■■ Federal Resources for Rural 
Communities to Help Address Substance 
Use Disorder and Opioid Misuse   
This Office of National Drug Control Policy, U.S. 
Department of Agriculture initiative includes the 
Community Resource Guide, a comprehensive 
directory of federal resources that can help rural 
communities address the opioid crisis. 
https://www.rd.usda.gov/files/RuralResource 
Guide.pdf
■■ Motivational Interviewing  
The SAMHSA-HRSA Center for Integrated Health 
Solutions provides resources for using motivational 
interviewing in substance use treatment to enhance 
motivation to change. 
https://www.integration.samhsa.gov/clinical-practice/
motivational-interviewing
■■ National Association of Drug Court 
Professionals (NADCP) 
In collaboration with ASAM and AAAP, NADCP 
developed a line of resources to educate drug court 
practitioners about the proven effects of MAT and 
provide tools to help programs adopt these treatments 
in a safe, effective, and responsible manner. 
https://www.ndci.org/resource/training/medication-
assisted-treatment/
■■ The Fortune Society  
The Fortune Society website has several resources 
to help decrease the use of stigmatizing language 
with individuals who are incarcerated or returning 
to the community. 
https://fortunesociety.org/
■■ Trauma-Informed Corrections 
This chapter of the fourth edition of Social Work in 
Juvenile and Criminal Justice System discusses how 
to provide trauma-informed services within a 
correctional environment. 
https://www.centerforgenderandjustice.org/assets/
files/soical-work-chapter-7-trauma-informed-
corrections-final.pdf
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